Nextgen Healthcare (NXGN) 10-K 27 May 21 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2021	May 24, 2021	Sep. 30, 2020
Cover [Abstract]
Entity Registrant Name	NEXTGEN HEALTHCARE, INC.
Trading Symbol	NXGN
Entity Central Index Key	0000708818
Document Type	10-K
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 704,935,000
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity File Number	001-12537
Entity Tax Identification Number	95-2888568
Entity Address, Address Line One	3525 Piedmont Rd., NE
Entity Address, Address Line Two	Building 6, Suite 700
Entity Address, City or Town	Atlanta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30305
City Area Code	(404)
Local Phone Number	467-1500
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.01 Par Value
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	CA
Document Annual Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		67,031,182
Documents Incorporated by Reference	Portions of the registrant's definitive proxy statement related to the 2021 Annual Shareholders' Meeting to be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended March 31, 2021 are incorporated herein by reference in Part III of this Annual Report on Form 10-K where indicated.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Current assets:
Cash and cash equivalents	$ 73,295,000	$ 138,012,000
Restricted cash and cash equivalents	5,280,000	2,307,000
Accounts receivable, net	77,541,000	80,006,000
Contract assets	19,481,000	12,529,000
Income taxes receivable	765,000	856,000
Prepaid expenses and other current assets	31,282,000	26,305,000
Total current assets	207,644,000	260,015,000
Equipment and improvements, net	14,539,000	19,836,000
Capitalized software costs, net	41,474,000	37,004,000
Operating lease assets	18,446,000	31,004,000
Deferred income taxes, net	19,474,000	10,620,000
Contract assets, net of current	1,976,000	3,007,000
Intangibles, net	36,700,000	57,809,000
Goodwill	267,212,000	267,165,000
Other assets	37,021,000	33,656,000
Total assets	644,486,000	720,116,000
Current liabilities:
Accounts payable	11,378,000	10,521,000
Contract liabilities	52,863,000	56,786,000
Accrued compensation and related benefits	50,374,000	23,792,000
Income taxes payable	584,000	148,000
Operating lease liabilities	12,735,000	10,619,000
Other current liabilities	52,699,000	41,352,000
Total current liabilities	180,633,000	143,218,000
Deferred compensation	6,620,000	5,300,000
Line of credit	0	129,000,000
Operating lease liabilities, net of current	18,453,000	38,823,000
Other noncurrent liabilities	7,136,000	3,281,000
Total liabilities	212,842,000	319,622,000
Commitments and contingencies (Note 16)
Shareholders' equity:
Common Stock, $0.01 par value; authorized 100,000 shares; issued and outstanding 67,069 and 66,134 shares at March 31, 2021 and March 31, 2020, respectively	671,000	661,000
Additional paid-in capital	304,263,000	282,857,000
Accumulated other comprehensive loss	(1,924,000)	(2,143,000)
Retained earnings	128,634,000	119,119,000
Total shareholders' equity	431,644,000	400,494,000
Total liabilities and shareholders' equity	$ 644,486,000	$ 720,116,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Mar. 31, 2020
Statement Of Financial Position [Abstract]
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	67,069,000	66,134,000
Common stock, shares outstanding	67,069,000	66,134,000

Consolidated Statements of Net

Consolidated Statements of Net Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Revenues:
Total revenues	$ 556,821	$ 540,239	$ 529,173
Cost of revenue:
Amortization of capitalized software costs and acquired intangible assets	36,768	35,478	28,490
Total cost of revenue	275,424	267,439	246,697
Gross profit	281,397	272,800	282,476
Operating expenses:
Selling, general and administrative	180,529	165,174	164,879
Research and development costs, net	75,501	83,295	80,994
Amortization of acquired intangible assets	4,449	4,143	4,344
Impairment of assets	5,539	12,571
Restructuring costs	2,562	2,505	640
Total operating expenses	268,580	267,688	250,857
Income from operations	12,817	5,112	31,619
Interest income	38	256	216
Interest expense	(3,516)	(1,955)	(2,814)
Other income (expense), net	(64)	846	267
Income before provision for (benefit of) income taxes	9,275	4,259	29,288
Provision for (benefit of) income taxes	(240)	(3,239)	4,794
Net income	9,515	7,498	24,494
Other comprehensive income:
Foreign currency translation, net of tax	219	(912)	(831)
Comprehensive income	$ 9,734	$ 6,586	$ 23,663
Net income per share:
Basic	$ 0.14	$ 0.11	$ 0.38
Diluted	$ 0.14	$ 0.11	$ 0.38
Weighted-average shares outstanding:
Basic	66,739	65,474	64,417
Diluted	66,885	65,612	64,600
Recurring
Revenues:
Total revenues	$ 502,819	$ 489,313	$ 473,921
Cost of revenue:
Cost of revenue excluding amortization of capitalized software costs and acquired intangible assets	212,199	205,057	191,496
Software, Hardware, and Other Non-recurring
Revenues:
Total revenues	54,002	50,926	55,252
Cost of revenue:
Cost of revenue excluding amortization of capitalized software costs and acquired intangible assets	$ 26,457	$ 26,904	$ 26,711

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Retained Earnings	Retained EarningsCumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss
Balance at Mar. 31, 2018	$ 323,410	$ 8,419	$ 640	$ 244,462	$ 78,708	$ 8,419	$ (400)
Balance, Shares at Mar. 31, 2018			63,995
Accounting Standards Update [Extensible List]		Accounting Standards Update 2014-09				Accounting Standards Update 2014-09
Common stock issued under stock plans, net of shares withheld for taxes	4,352		$ 8	4,344
Common stock issued under stock plans, net of shares withheld for taxes, Shares			843
Stock-based compensation	16,102			16,102
Other comprehensive income:
Translation adjustments	(831)						(831)
Net income	24,494				24,494
Balance at Mar. 31, 2019	375,946		$ 648	264,908	111,621		(1,231)
Balance, Shares at Mar. 31, 2019			64,838
Common stock issued under stock plans, net of shares withheld for taxes	(1,732)		$ 13	(1,745)
Common stock issued under stock plans, net of shares withheld for taxes, Shares			1,296
Stock-based compensation	19,694			19,694
Other comprehensive income:
Translation adjustments	(912)						(912)
Net income	7,498				7,498
Balance at Mar. 31, 2020	400,494		$ 661	282,857	119,119		(2,143)
Balance, Shares at Mar. 31, 2020			66,134
Common stock issued under stock plans, net of shares withheld for taxes	(1,294)		$ 10	(1,304)
Common stock issued under stock plans, net of shares withheld for taxes, Shares			935
Stock-based compensation	22,710			22,710
Other comprehensive income:
Translation adjustments	219						219
Net income	9,515				9,515
Balance at Mar. 31, 2021	$ 431,644		$ 671	$ 304,263	$ 128,634		$ (1,924)
Balance, Shares at Mar. 31, 2021			67,069

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net income	$ 9,515	$ 7,498	$ 24,494
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of capitalized software costs	20,108	17,085	11,338
Amortization and write-off of debt issuance costs	1,026	710	710
Amortization of other intangibles	21,109	22,536	21,496
Change in fair value of contingent consideration	(1,367)	(950)	1,000
Deferred income taxes	(8,854)	(5,379)	245
Depreciation	7,997	8,172	10,298
Excess tax deficiency (benefit) from share-based compensation	798	(53)	(365)
Impairment of assets	5,539	12,571
Loss on disposal of equipment and improvements	12	41	194
Non-cash operating lease costs	6,786	8,108
Provision for bad debts	2,834	3,367	5,644
Share-based compensation	22,710	19,694	16,102
Changes in assets and liabilities, net of amounts acquired:
Accounts receivable	(369)	4,937	(6,178)
Contract assets	(5,921)	1,458	(812)
Accounts payable	615	3,330	1,070
Contract liabilities	(3,923)	(133)	(4,131)
Accrued compensation and related benefits	26,582	(2,419)	(2,992)
Income taxes	1,615	2,454	4,049
Deferred compensation	1,320	(605)	(181)
Operating lease liabilities	(16,736)	(9,684)
Other assets and liabilities	7,122	(7,137)	(31,506)
Net cash provided by operating activities	98,518	85,601	50,475
Cash flows from investing activities:
Additions to capitalized software costs	(24,578)	(19,432)	(20,571)
Additions to equipment and improvements	(3,761)	(7,449)	(4,952)
Acquisition related working capital adjustment payments	(206)
Payments for acquisitions, net of cash acquired		(71,691)
Proceeds from over-funded corporate-owned life insurance policies		2,500
Net cash used in investing activities	(28,545)	(96,072)	(25,523)
Cash flows from financing activities:
Proceeds from line of credit	50,000	137,000	26,000
Repayments on line of credit	(179,000)	(19,000)	(52,000)
Payment of debt issuance costs	(1,423)
Proceeds from issuance of shares under employee plans	3,479	2,409	7,533
Payments for taxes related to net share settlement of equity awards	(4,773)	(4,141)	(3,181)
Net cash provided by (used in) financing activities	(131,717)	116,268	(21,648)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(61,744)	105,797	3,304
Cash, cash equivalents, and restricted cash at beginning of period	140,319	34,522	31,218
Cash, cash equivalents, and restricted cash at end of period	78,575	140,319	34,522
Supplemental disclosures of cash flow information:
Cash paid for income taxes	6,206	2,599	1,570
Cash refunds from income taxes	155	2,728	675
Cash paid for interest	2,708	1,266	1,819
Non-cash investing and financing activities:
Non-cash additions to capitalized software			2,304
Cash paid for amounts included in the measurement of operating lease liabilities	18,651	11,527
Operating lease assets obtained in exchange for operating lease liabilities	3,107	8,494
Accrued purchases of equipment and improvements	$ 242	$ 173	$ 149

Organization of Business

Organization of Business	12 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization of Business	1. Organization of Business Description of Business NextGen Healthcare is a leading provider of software and services that empower ambulatory healthcare practices to manage the risk and complexity of delivering care in the rapidly evolving U.S. healthcare system. Our combination of technological breadth, depth and domain expertise makes us a preferred solution provider and trusted advisor for our clients. In addition to highly configurable core clinical and financial capabilities, our portfolio includes tightly integrated solutions that deliver on ambulatory healthcare imperatives including: population health, care management, patient outreach, telemedicine, and nationwide clinical information exchange. We serve clients across all 50 states. Over 100,000 providers use NextGen Healthcare solutions to deliver care in nearly every medical specialty in a wide variety of practice models including accountable care organizations (“ACOs”), independent physician associations (“IPAs”), managed service organizations (“MSOs”), Veterans Service Organizations (“VSOs”), and Dental Service Organizations (“DSOs”). Our clients include some of the largest and most progressive multi-specialty groups in the country. With the addition of behavioral health to our medical and oral health capabilities, we continue to extend our share not only in Federally Qualified Health Centers (“FQHCs”), but also in the growing integrated care market. NextGen Healthcare has historically enhanced our offering through both organic and inorganic activities. In October 2015, we divested our former Hospital Solutions division to focus exclusively on the ambulatory marketplace. In January 2016, we acquired HealthFusion Holdings, Inc. and its cloud-based electronic health record and practice management solution. In April 2017, we acquired Entrada, Inc. and its cloud-based, mobile platform for clinical documentation and collaboration. In August 2017, we acquired EagleDream Health, Inc. and its cloud-based population health analytics solution. In January 2018, we acquired Inforth Technologies for its specialty-focused clinical content. In October 2019, we acquired Topaz Information Systems, LLC for its behavioral health solutions. In December 2019, we acquired Medfusion, Inc. for its Patient Experience Platform (i.e., patient portal, self-scheduling, and patient pay) capabilities and OTTO Health, LLC for its integrated virtual care solutions, notably telemedicine. The integration of these acquired technologies has made NextGen Healthcare’s solutions among the most comprehensive in the market. Our company was incorporated in California in 1974. Previously named Quality Systems, Inc., we changed our corporate name to NextGen Healthcare, Inc. in September 2018. Our principal executive offices are located at 3525 Piedmont Rd., NE, Building 6, Suite 700, Atlanta, Georgia, and our principal website is www.nextgen.com. We operate on a fiscal year ending on March 31.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation. The consolidated financial statements include the accounts of NextGen Healthcare, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Each of the terms “NextGen Healthcare,” “NextGen,” “we,” “us,” or “our” as used herein refers collectively to the Company, unless otherwise stated. All intercompany accounts and transactions have been eliminated. Business Segments. We operated as one segment for the years ended March 31, 2021 and 2020. The measures evaluated by our chief operating decision maker ("CODM"), consisting of our Chief Executive Officer, to assess company performance and make decisions about the allocation of resources include consolidated revenue and consolidated operating results. Basis of Presentation. References to amounts in the consolidated financial statement sections are in thousands, except shares and per share data, unless otherwise specified. Coronavirus Pandemic. In late 2019, the emergence of a novel coronavirus, or COVID-19, was reported and in January 2020, the World Health Organization (“WHO”), declared it a Public Health Emergency of International Concern. In March 2020, the WHO escalated COVID-19 as a pandemic. The extent to which COVID-19 may continue to impact our business and financial results depends on numerous evolving factors including, but not limited to, the magnitude and duration of COVID-19; the impact on our employees; the extent to which it impacts worldwide macroeconomic conditions, including interest rates, employment rates, and health insurance coverage; the speed of the recovery; and governmental and business reactions to the pandemic. We assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 at March 31, 2021, and through the date of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, our allowances for doubtful accounts and the carrying value of goodwill and other long-lived assets. While there was not a material impact to our consolidated financial statements at and for the year-ended March 31, 2021, our future assessment of the magnitude and duration of COVID-19, as well as other factors could result in material impacts to our consolidated financial statements in future reporting periods. Use of Estimates. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), which requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and recording revenue and expenses during the period. Revenue Recognition . We adopted Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) and all related amendments as of April 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption and recorded an adjustment to retained earnings as of April 1, 2018 due to the cumulative impact of adopting ASC 606. Refer to Note 3, "Revenue from Contracts with Customers" for additional information regarding our revenue recognition policies. Cash and Cash Equivalents. Cash and cash equivalents consist primarily of cash and money market funds with original maturities of less than 90 days. At March 31, 2021 and March 31, 2020, we had cash and cash equivalents of $73,295 and $138,012, respectively. We also had cash deposits held at United States banks and financial institutions at March 31, 2021 of which $86,317 was in excess of the Federal Deposit Insurance Corporation insurance limit of $250 per owner. Our cash deposits are exposed to credit loss for amounts in excess of insured limits in the event of nonperformance by the institutions; however, we do not anticipate nonperformance by these institutions. Money market funds in which we hold a portion of our excess cash are invested in very high grade commercial and governmental instruments, and therefore bear low market risk. Restricted Cash and Cash Equivalents. Restricted cash and cash equivalents consist of cash that is being held by the Company acting as an agent for the disbursement of certain state social and care services programs. We record an offsetting liability when we initially receive such cash from the programs. We relieve both restricted cash and cash equivalents and the related liability when amounts are disbursed. We earn an administrative fee based on a percentage of the funds disbursed on behalf of the government social and care service programs. Reserves on Accounts Receivable. We maintain reserves for estimated potential sales returns and uncollectible accounts receivable. Accounts receivable are reported net of uncollectible accounts receivable on our consolidated balance sheets. Our standard contracts generally do not contain provisions for clients to return products or services. However, we historically have accepted sales returns under limited circumstances. We estimate expected sales returns and other forms of variable consideration considering our customary business practice and contract-specific facts and circumstances, and we consider such estimated potential returns as variable consideration when allocating the transaction price to the extent it is probable that there will not be a significant reversal of cumulative revenue recognized. We adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments on April 1, 2020 Allowances for doubtful accounts and other uncollectible accounts receivable related to estimated losses resulting from our clients’ inability to make required payments are established based on our assessment of the collectability of client accounts, including review of our historical experience of bad debt expense and the aging of our accounts receivable balances, net of specifically reserved accounts and amounts billed prior to revenue recognition. Specific reserves are based on our estimate of the probability of collection for certain accounts. As part of our assessment of the adequacy of the allowance for doubtful accounts, we considered a number of factors including, but not limited to, historical credit loss experience and adjustments for certain asset-specific risk characteristics, such as bankruptcy filings, internal assessments of client credit quality, age of the client receivable balances, review of major third-party credit-rating agencies, and evaluation of external factors such as economic conditions, including the potential impacts of the COVID-19 pandemic, that may affect a client’s ability to pay, or other client-specific factors. Accounts are written off as uncollectible only after we have expended extensive collection efforts. Refer to Note 4, “Accounts Receivable” for additional information. Leases. We adopted ASU 2016-02, Leases (Topic 842) , and its subsequent amendments (together “ASC 842”) using the cumulative-effect adjustment transition method, which is the additional transition method described within ASU 2018-11, Leases (Topic 842): Targeted Improvements , issued by the FASB in July 2018, which allowed us to apply the new lease standard as of April 1, 2019, rather than the beginning of the earliest period presented. Our leasing arrangements are reflected on the balance sheet as right-of-use assets and liabilities pertaining to the rights and obligations created by the leased assets. We determine whether an arrangement is a lease at inception and classify it as finance or operating. All of our existing material leases are classified as operating leases. Our leases do not contain any residual value guarantees. Right-of-use lease assets and corresponding lease liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since the interest rate implicit in our lease arrangements is not readily determinable, we determine an incremental borrowing rate for each lease based on the approximate interest rate on a collateralized basis with similar remaining terms and payments as of the lease commencement date to determine the present value of future lease payments. Our lease terms may include options to extend or terminate the lease. Currently, it is not reasonably certain that we will exercise those options and therefore, we utilize the initial, noncancelable, lease term to calculate the lease assets and corresponding liabilities for all our leases. We have certain insignificant short-term leases with an initial term of twelve months or less that are not recorded in our consolidated balance sheets. Operating right-of-use lease assets are classified as operating lease assets on our consolidated balance sheets. Our lease agreements generally contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. We have applied the practical expedient to combine fixed payments for non-lease components with our lease payments for all of our leases and account for them together as a single lease component, which increases the amount of our lease assets and corresponding liabilities. Payments under our lease arrangements are primarily fixed, however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease assets and liabilities. Operating lease costs are recognized on a straight-line basis over the lease term and included as a selling, general and administrative expense in the consolidated statements of net income and comprehensive income. Refer to Note 6, "Leases" for additional information. Equipment and Improvements. Equipment and improvements are stated at cost less accumulated depreciation and amortization. Repair and maintenance costs that do not improve service potential or extend economic life are expensed as incurred. Depreciation and amortization of equipment and improvements are recorded over the estimated useful lives of the assets, or the related lease terms if shorter, by the straight-line method. Useful lives generally have the following ranges: • Computer equipment and software - 3 to 5 years • Furniture and fixtures - 3 to 7 years • Leasehold improvements - lesser of lease term or estimated useful life of asset Depreciation expense related to our equipment and improvements was $7,997 Capitalized Software Costs. Software development costs, consisting primarily of employee salaries and benefits and certain third party costs, incurred in the development of new software solutions and enhancements to existing software solutions for external sale are expensed as incurred, and reported as net research and development costs in the consolidated statements of net income and comprehensive income, until technological feasibility has been established. After technological feasibility is established, any additional software development costs are capitalized. Amortization of capitalized software is recorded on a straight-line basis over the estimated economic life of the related product, which is typically three years. The total of capitalized software costs incurred in the development of products for external sale are reported as capitalized software costs within our consolidated balance sheets. We also incur costs related to the development of software applications for our internal-use and for the development of software-as-a-service ("SaaS") based solutions sold to our clients. The development costs of our SaaS-based solutions are considered internal-use for accounting purposes. Our internal-use capitalized development costs are stated at cost and amortized on a straight-line basis over the estimated useful lives of the assets, which is typically three years. Application development stage costs generally include costs associated with internal-use software configuration, coding, installation and testing. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Costs of significant upgrades and enhancements that result in additional functionality are also capitalized, whereas costs incurred for maintenance and minor upgrades and enhancements are expensed as incurred. Capitalized software costs for the development of SaaS-based solutions are reported as capitalized software costs within our consolidated balance sheets and capitalized software costs for the development of our internal-use software applications are reported as equipment and improvements within our consolidated balance sheets. We periodically reassess the estimated economic life and the recoverability of our capitalized software costs. If we determine that capitalized amounts are not recoverable based on the expected net cash flows to be generated from sales of the applicable software solutions, the amount by which the unamortized capitalized costs exceed the net realizable value is written off as a charge to earnings. The net realizable value is estimated as the expected future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility at the time of sale. In addition to the assessment of net realizable value, we review and adjust the remaining estimated lives of our capitalized software costs, if necessary. We also perform a periodic review of our software solutions and dispose of fully amortized capitalized software costs after such products are determined to no longer be used by our clients. Business Combinations. In accordance with the accounting for business combinations, we allocate the purchase price of the acquired business to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The fair values of acquired assets and liabilities assumed represent our best estimate of fair value. The estimated fair value of the acquired tangible and intangible assets and liabilities assumed were determined using multiple valuation approaches depending on the type and nature of tangible or intangible asset acquired or liabilities assumed, including but not limited to the income approach, the excess earnings method and the relief from royalty method approach. The purchase price allocation methodology contains uncertainties as it requires us to make assumptions and to apply judgment to estimate the fair value of acquired assets and liabilities, including, but not limited to, intangible assets, goodwill, deferred revenue, and contingent consideration liabilities. We estimate the fair value of the contingent consideration liabilities, as needed, based on our projection of expected results and the estimated probability of achievement. The process to develop the estimate of fair values in many cases requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. Unanticipated events or circumstances may occur which could affect the accuracy of our fair value estimates, including assumptions regarding industry economic factors and business strategies. We expect to finalize the purchase price allocation as soon as practicable within the measurement period, but not later than one year following the acquisition date. Any adjustments to fair value subsequent to the measurement period are reflected in the consolidated statements of net income and comprehensive income. Goodwill. Goodwill acquired in a business combination is measured as the excess of the purchase price, or consideration transferred, over the net acquisition date fair values of the assets acquired and the liabilities assumed. Goodwill is not amortized as it has been determined to have an indefinite useful life. We test goodwill for impairment annually during our first fiscal quarter, referred to as the annual test date. We will also test for impairment between annual test dates if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting-unit level, which is defined as an operating segment or one level below an operating segment (referred to as a component). We operate as one segment and have a single reporting unit. The measures evaluated by our chief operating decision maker ("CODM"), consisting of our Chief Executive Officer, to assess company performance and make decisions about the allocation of resources include consolidated revenue and consolidated operating results. As part of our annual goodwill impairment test, we may elect to first assess qualitative factors to determine whether it is more likely than not that the fair value of our single reporting unit is less than its carrying amount. We assess events or changes in circumstances in totality, including macroeconomic and industry conditions, market and competitive environment, changes in customers or customer mix, cost factors, loss of key personnel, significant changes in legislative environment or other legal factors, changes in the use of our acquired assets, changes in our strategic direction, significant changes in projected future results of operations, changes in the composition or carrying amount of our net assets, and changes in our stock price. Based on our assessment, if we conclude that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then additional impairment testing is not required. Otherwise, if we determine that a quantitative impairment test should be performed, we then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit with its book value, including goodwill. If the estimated fair value exceeds book value, goodwill is considered not to be impaired and no additional steps are necessary. If, however, the fair value of the reporting unit is less than book value, then an impairment charge is recorded for the difference between the reporting unit’s fair value and carrying amount, not to exceed the carrying amount of the goodwill. Intangible Assets. Intangible assets consist of trade names, customer relationships, and software technology, all of which are associated with our acquisitions. The intangible assets are recorded at fair value and are reported net of accumulated amortization. We currently amortize the intangible assets over periods ranging from 5 to 10 years using a method that reflects the pattern in which the economic benefits of the intangible asset are consumed. We assess the recoverability of intangible assets at least annually or whenever adverse events or changes in circumstances indicate that impairment may have occurred. If the future undiscounted cash flows expected to result from the use of the related assets are less than the carrying value of such assets, impairment is deemed to have occurred and a loss is recognized to reduce the carrying value of the intangible assets to fair value, which is determined by discounting estimated future cash flows. In addition to the impairment assessment, we routinely review the remaining estimated lives of our intangible assets and record adjustments, if deemed necessary. Long-Lived Assets. We assess our long-lived assets for potential impairment periodically or whenever adverse events or changes in circumstances indicate that impairment may have occurred. If necessary, recoverability of the assets is evaluated based on the future undiscounted cash flows expected to result from the use of the related assets compared to the carrying value of such assets. If impairment is deemed to have occurred, a loss is recognized to reduce the carrying value of the long-lived assets to fair value, which is determined by discounting the estimated future cash flows. In addition to the impairment assessment, we routinely review the remaining estimated lives of our long-lived assets and record adjustments, if deemed necessary. Income Taxes. Income taxes are provided based on current taxable income and the future tax consequences of temporary differences between the basis of assets and liabilities for financial and tax reporting. The deferred income tax assets and liabilities represent the future state and federal tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred income taxes are also recognized for operating losses that are available to offset future taxable income and tax credits that are available to offset future income taxes. At each reporting period, we assess the realizable value of deferred tax assets based on, among other things, estimates of future taxable income and adjust the related valuation allowance as necessary. We make a number of assumptions and estimates in determining the appropriate amount of expense to record for income taxes. The assumptions and estimates consider the taxing jurisdiction in which we operate as well as current tax regulations. Accruals are established for estimates of tax effects for certain transactions and future projected profitability based on our interpretation of existing facts and circumstances. Advertising Costs. Advertising costs are expensed as incurred. We do not have any direct-response advertising. Advertising costs, which include trade shows and conventions, were approximately $3,902, $6,044, and $8,226 for the years ended March 31, 2021, 2020, and 2019, respectively, and were included in selling, general and administrative expenses in the accompanying consolidated statements of net income and comprehensive income. Earnings per Share. We provide a dual presentation of “basic” and “diluted” earnings per share (“EPS”). Shares below are in thousands. Fiscal Year Ended March 31, 2021 2020 2019 Earnings per share — Basic: Net income $ 9,515 $ 7,498 $ 24,494 Weighted-average shares outstanding — Basic 66,739 65,474 64,417 Net income per common share — Basic $ 0.14 $ 0.11 $ 0.38 Earnings per share — Diluted: Net income $ 9,515 $ 7,498 $ 24,494 Weighted-average shares outstanding 66,739 65,474 64,417 Effect of potentially dilutive securities 146 138 183 Weighted-average shares outstanding — Diluted 66,885 65,612 64,600 Net income per common share — Diluted $ 0.14 $ 0.11 $ 0.38 The computation of diluted net income per share does not include 1,949, 1,807 and 1,963 options for the years ended March 31, 2021, 2020, and 2019, respectively, because their inclusion would have an anti-dilutive effect on net income per share. Share-Based Compensation. The following table shows total share-based compensation expense included in the consolidated statements of net income and comprehensive income for the fiscal year ended March 31, 2021, 2020, and 2019: Fiscal Year Ended March 31, 2021 2020 2019 Costs and expenses: Cost of revenue $ 1,991 $ 2,051 $ 1,252 Research and development costs 4,036 3,875 2,919 Selling, general and administrative 16,683 13,768 11,931 Total share-based compensation 22,710 19,694 16,102 Income tax benefit (5,415 ) (4,726 ) (3,859 ) Decrease in net income $ 17,295 $ 14,968 $ 12,243 Recently Adopted Accounting Pronouncements. Recently adopted accounting pronouncements are discussed below or in the notes, where applicable. In August 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-15, Intangibles–Goodwill and Other–Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework–Changes to the Disclosure Requirements for Fair Value Measurement In January 2017, the FASB issued ASU 2017-04, Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recent Accounting Standards Not Yet Adopted. Recent accounting pronouncements requiring implementation in current or future periods are discussed below or in the notes, where applicable. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting Reference Rate Reform (Topic 848): Scope Topic 848 amended and restated revolving credit agreement Topic 848 e are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance on our consolidated financial statements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes e do not expect the adoption of this new standard to have a material impact on our consolidated financial statements We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue from Contract with Customer	3. Revenue from Contracts with Customers Revenue Recognition and Performance Obligations We generate revenue from sales of licensing rights and subscriptions to our software solutions, hardware and third-party software products, support and maintenance, managed services, EDI, and other non-recurring services, including implementation, training, and consulting services. Our contracts with customers may include multiple performance obligations that consist of various combinations of our software solutions and related services, which are generally capable of being distinct and accounted for as separate performance obligations. The total transaction price is allocated to each performance obligation within a contract based on estimated standalone selling prices. We generally determine standalone selling prices based on the prices charged to customers, except for certain software licenses that are based on the residual approach because their standalone selling prices are highly variable and certain maintenance customers that are based on substantive renewal rates. In instances where standalone selling price is not sufficiently observable, such as RCM services and software licenses included in our RCM arrangements, we estimate standalone selling price utilizing an expected cost plus a margin approach. When standalone selling prices are not observable, significant judgment is required in estimating the standalone selling price for each performance obligation. Revenue is recognized when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration that we expect to be entitled to in exchange for those goods or services. We exclude sales tax from the measurement of the transaction price and record revenue net of taxes collected from customers and subsequently remitted to governmental authorities. The following table presents our revenues disaggregated by our major revenue categories and by occurrence: Fiscal Year Ended March 31, 2021 2020 2019 Recurring revenues: Subscription services $ 148,403 $ 127,602 $ 117,502 Support and maintenance 152,956 158,619 160,798 Managed services 103,138 104,549 98,203 Electronic data interchange and data services 98,322 98,543 97,418 Total recurring revenues 502,819 489,313 473,921 Software, hardware, and other non-recurring revenues: Software license and hardware 28,825 27,270 35,122 Other non-recurring services 25,177 23,656 20,130 Total software, hardware and other non-recurring revenues 54,002 50,926 55,252 Total revenues $ 556,821 $ 540,239 $ 529,173 Recurring revenues consists of subscription services, support and maintenance, managed services, and EDI and data services. Software, hardware, and other non-recurring revenues consists of revenue from sales of software license and hardware and certain non-recurring services, such as implementation, training, and consulting performed for clients who use our products. We generally recognize revenue for our most significant performance obligations as follows: Subscription services. Performance obligations involving subscription services, which include annual libraries, are satisfied over time as the customer simultaneously receives and consumes the benefits of the services throughout the contract period. Our subscription services primarily include our software-as-a-service (“SaaS”) based offerings, such as our electronic health records and practice management, mobile, patient portal, and population health management solutions. Our SaaS-based offerings may include multiple goods and services, such as providing access to our technology-based solutions together with our managed cloud hosting services. These offerings are concurrently delivered with the same pattern of transfer to our customers and are accounted for as a single performance obligation because the technology-based solutions and other goods and services included within our overall SaaS-based offerings are each individually not capable of being distinct as the customer receives benefits based on the combined offering. Our annual libraries primarily consist of providing stand-ready access to certain content, knowledgebase, databases, and SaaS-based educational tools, which are frequently updated to meet the most current standards and requirements, to be utilized in conjunction with our core solutions. We recognize revenue related to these subscription services, including annual libraries, ratably over the respective noncancelable contract term. Support and maintenance. Performance obligations involving support and maintenance are satisfied over time as the customer simultaneously receives and consumes the benefits of the maintenance services provided. Our support and maintenance services may consist of separate performance obligations, such as unspecified upgrades or enhancements and technical support, which are considered stand-ready in nature and can be offered at various points during the service period. Since the efforts associated with the combined support and maintenance services are rendered concurrently and provided evenly throughout the service period, we consider the series of support and maintenance services to be a single performance obligation. Therefore, we recognize revenue related to these services ratably over the respective noncancelable contract term. Managed services. Managed services consist primarily of RCM and related services, but also includes our hosting services, which we refer to as managed cloud services, transcription services, patient pay services, and certain other recurring services. Performance obligations associated with RCM services are satisfied over time as the customer simultaneously receives and consumes the benefits of the services executed throughout the contract period. The majority of service fees under our RCM arrangements are variable consideration contingent upon collections by our clients. We estimate the variable consideration which we expect to be entitled to over the noncancelable contract term associated with our RCM service arrangements. The estimate of variable consideration included in the transaction price typically involves estimating the amounts we will ultimately collect on behalf of our clients and the relative fee we charge that is generally calculated as a percentage of those collections. Inputs to these estimates include, but are not limited to, historical service fees and collections amounts, timing of historical collections relative to the timing of when claims are submitted by our clients to their respective payers, macroeconomic trends, and anticipated changes in the number of providers. Significant judgement is required when estimating the total transaction price based on the variable consideration. We may apply certain constraints when appropriate whereby we include in the transaction price estimated variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Such estimates are assessed at the contract level. RCM and related services may not be rendered evenly over the contract period as the timing of services are based on customer collections, which may vary throughout the service period. We recognize revenue for RCM based on the amount of collections received throughout the contract term as it most closely depicts our efforts to transfer our service obligations to the customer. Our managed cloud services represent a single performance obligation to provide cloud hosting services to our customers and related revenue is recognized ratably over the respective noncancelable contract term. Performance obligations related to the transcription services , patient pay services, and other recurring services are satisfied as the corresponding services are provided and revenue is recognized as such services are rendered. Electronic data interchange and data services. Performance obligations related to EDI and other transaction processing services are satisfied at the point in time the services are rendered. The transfer of control occurs when the transaction processing services are delivered and the customer receives the benefits from the services provided. Software license and hardware. Software license and hardware are considered point-in-time performance obligations as control is transferred to customers upon the delivery of the software license and hardware. Our software licenses are considered functional licenses, and revenue recognition generally occurs on the date of contract execution as the customer is provided with immediate access to the license. We generally determine the amount of consideration allocated to the software license performance obligation using the residual approach, except for certain RCM arrangements where the amount allocated to the software license performance obligation is determined based on estimated relative standalone selling prices. For hardware, we recognize revenue upon transfer of such hardware or devices to the customer. Other non-recurring services. Performance obligations related to other non-recurring services, including implementation, training, and consulting services, are generally satisfied as the corresponding services are provided. Once the services have been provided to the customer, the transfer of control has occurred. Therefore, we recognize revenue as such services are rendered. Transaction Price Allocated to Remaining Performance Obligations As of March 31, 2021, the aggregate amount of transaction price related to remaining unsatisfied or partially unsatisfied performance obligations over the respective noncancelable contract term was approximately $548,800 of which we expect to recognize approximately 9% as services are rendered or goods are delivered , 53% As of March 31, 2020, the aggregate amount of transaction price related to remaining unsatisfied or partially unsatisfied performance obligations over the respective noncancelable contract term was approximately $483,200, of which we expect to recognize approximately 9% as services are rendered or goods are delivered, 50% over the next 12 months, and the remainder thereafter. Contract Balances Contract balances result from the timing differences between our revenue recognition, invoicing, and cash collections. Such contract balances include accounts receivables, contract assets and liabilities, and other customer deposits and liabilities balances. Accounts receivables include invoiced amounts where the right to receive payment is unconditional and only subject to the passage of time. Contract assets, consisting of unbilled receivables, include amounts where revenue recognized exceeds the amount invoiced to the customer and the right to payment is not solely subject to the passage of time. Contract assets are generally associated with our sales of software licenses, but may also be associated with other performance obligations such as subscription services, support and maintenance, annual libraries, and professional services, where control has been transferred to our customers but the associated payments are based on future customer collections (in the case of our RCM service arrangements) or based on future milestone payment due dates. In such instances, the revenue recognized may exceed the amount invoiced to the customer and such balances are included in contract assets since our right to receive payment is not unconditional, but rather is conditional upon customer collections or the continued functionality of the software and our ongoing support and maintenance obligations. Contract liabilities consist mainly of fees invoiced or paid by our clients for which the associated services have not been performed and revenues have not been recognized. Contract assets and contract liabilities are reported in a net position on an individual contract basis at the end of each reporting period. Contract assets are classified as current or long-term on our consolidated balance sheets based on the timing of when we expect to complete the related performance obligations and invoice the customer. Contract liabilities are classified as current on our consolidated balance sheets since the revenue recognition associated with the related customer payments and invoicing is expected to occur within the next twelve months. During the years ended March 31, 2021 and 2020, we recognized $74,097 and $70,779, respectively, of revenues that were included in the contract liability balance or invoiced to customers since the beginning of the corresponding periods. Our contracts with customers do not include any major financing components. Costs to Obtain or Fulfill a Contract We capitalize all incremental costs of obtaining a contract with a customer to the extent that such costs are directly related to a contract and expected to be recoverable. Our sales commissions and related sales incentives are considered incremental costs requiring capitalization. Capitalized contract costs are amortized to expense utilizing a method that is consistent with the transfer of the related goods or services to the customer. The amortization period ranges from less than one year up to five years, based on the period over which the related goods and services are transferred, including consideration of the expected customer renewals and the related useful lives of the products. Capitalized commissions costs were $28,503 as of March 31, 2021, of which $9,399 is classified as current and included as prepaid expenses and other current assets and $19,104 is classified as long-term and included within other assets on our consolidated balance sheets, based on the expected timing of expense recognition. Capitalized commissions costs were $24,590 as of March 31, 2020, of which $7,053 was classified as current and $17,537 was classified as long-term. During the years ended March 31, 2021, 2020, and 2019, we recognized $11,236, $8,006, and $6,292, respectively, of commissions expense. Commissions expense primarily relate to the amortization of capitalized commissions costs, which is included as a selling, general and administrative expense in the consolidated statements of net income and comprehensive income.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Accounts Receivable	4. Accounts Receivable Accounts receivable includes invoiced amounts where the right to receive payment is unconditional and only subject to the passage of time. Allowance for doubtful accounts are reported as a component of accounts receivable as summarized below: March 31, 2021 March 31, 2020 Accounts receivable, gross $ 81,746 $ 83,555 Allowance for doubtful accounts (4,205 ) (3,549 ) Accounts receivable, net $ 77,541 $ 80,006 The following table represents the changes in the allowance for doubtful accounts, as of and for the twelve months ended March 31, 2021 and 2020: Balance as of March 31, 2019 $ (6,054 ) Additions charged to costs and expenses (3,367 ) Deductions 5,872 Balance as of March 31, 2020 (3,549 ) Additions charged to costs and expenses (2,834 ) Deductions 2,178 Balance as of March 31, 2021 $ (4,205 )

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements The following tables set forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis at March 31, 2021 and March 31, 2020: Balance At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Unobservable Inputs March 31, 2021 (Level 1) (Level 2) (Level 3) ASSETS Cash and cash equivalents (1) $ 73,295 $ 73,295 $ — $ — Restricted cash and cash equivalents 5,280 5,280 — — $ 78,575 $ 78,575 $ — $ — LIABILITIES Contingent consideration related to acquisitions $ 533 $ — $ 533 $ — $ 533 $ — $ 533 $ — Balance At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Unobservable Inputs March 31, 2020 (Level 1) (Level 2) (Level 3) ASSETS Cash and cash equivalents (1) $ 138,012 $ 138,012 $ — $ — Restricted cash and cash equivalents 2,307 2,307 — — $ 140,319 $ 140,319 $ — $ — LIABILITIES Contingent consideration related to acquisitions $ 1,900 $ — $ — $ 1,900 $ 1,900 $ — $ — $ 1,900 (1) Cash equivalents consist primarily of money market funds. The following table presents activity in our financial assets and liabilities measured at fair value using significant unobservable inputs (Level 3), as of and for the year ended March 31, 2021: Balance at March 31, 2019 $ 1,000 Acquisition 1,850 Fair value adjustments (950 ) Balance at March 31, 2020 1,900 Fair value adjustments (1,367 ) Transfer of Topaz contingent consideration to Level 2 (533 ) Balance at March 31, 2021 $ — As of March 31, 2021 and March 31, 2020, the contingent consideration liability balances were $533 and $1,900, respectively, which were related to the acquisition of Topaz Information Systems, LLC. During the year ended March 31, 2020, we recorded a net benefit of $950 from fair value adjustments, of which a $1,000 benefit was related to the contingent consideration liability from the acquisition of Inforth Technologies and was based on actual earnout achievement through the end of the measurement period, resulting in zero expected earnout payments, and $50 was related to the accretion of the present value discount of the contingent consideration liability from the acquisition of Topaz Information Systems, LLC. During the year ended March 31, 2021, we recorded a net benefit of $1,367 from fair value adjustments, which was related to the contingent consideration liability from the acquisition of Topaz Information Systems, LLC. As of March 31, 2021, the fair value of the contingent consideration liability was $533, calculated based on actual earnout achievement through the end of the performance period and is reflected under a Level 2 valuation hierarchy because the fair value was determined based on other significant observable inputs. Refer to Note 7 for additional details. The categorization of the framework used to measure fair value of the contingent consideration liabilities were considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used. We had assessed the fair value of the contingent consideration liability on a recurring basis and any adjustments to fair value subsequent to the measurement period were reflected in the consolidated statements of net income and comprehensive income. Key assumptions included probability-adjusted achievement estimates of applicable bookings targets that were not observable in the market. The fair value adjustments to contingent consideration liabilities are included as a component of selling, general and administrative expense in the consolidated statements of net income and comprehensive income. We believe that the fair value of other financial assets and liabilities, including accounts receivable, accounts payable, and line of credit, approximate their respective carrying values due to their nominal credit risk. Non-Recurring Fair Value Measurements We have certain assets, including goodwill and other intangible assets, which are measured at fair value on a non-recurring basis and are adjusted to fair value only if an impairment charge is recognized. The categorization of the framework used to measure fair value of the assets is considered to be within the Level 3 valuation hierarchy due to the subjective nature of the unobservable inputs used.

Leases

Leases	12 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	6. Leases We have operating lease agreements for our offices in the United States and India with lease periods expiring between 2021 and 2026. Total operating lease costs were $9,190, $10,309, and $8,174 for the years ended March 31, 2021, 2020, and 2019, respectively. Components of operating lease costs are summarized as follows: Fiscal Year Ended March 31, 2021 2020 Operating lease costs $ 8,235 $ 9,558 Short-term lease costs 25 102 Variable lease costs 1,444 827 Less: Sublease income (514 ) (178 ) Total operating lease costs $ 9,190 $ 10,309 Supplemental cash flow information related to operating leases is summarized as follows: Fiscal Year Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 18,651 $ 11,527 Operating lease assets obtained in exchange for operating lease liabilities 3,107 8,494 As of March 31, 2021, our operating leases had a weighted average remaining lease term of 3.1 years and a weighted average discount rate of 3.5%. Future minimum aggregate lease payments under operating leases as of March 31, 2021 are summarized as follows: For the year ended March 31, 2022 $ 13,725 2023 8,220 2024 6,272 2025 3,790 2026 1,257 Total future lease payments 33,264 Less interest (2,076 ) Total lease liabilities $ 31,188 During the year ended March 31, 2021, as part of our response to the COVID-19 pandemic and ongoing cost reduction efforts, we vacated our Cary office, portions of our Irvine and Horsham offices, and the remainder of our San Diego office. We recorded impairments of $5,539 to our operating right-of-use assets and certain related fixed assets associated with the vacated locations based on projected sublease rental income and estimated sublease commencement dates and the remeasurement of our operating lease liabilities associated with the modification of certain lease expiration dates. The impairment analyses were performed by operating right-of-use asset operating right-of-use asset operating right-of-use asset During the year ended March 31, 2020, we recorded impairments of $9,373 to our operating right-of-use assets and certain related fixed assets associated with the vacated locations, or portions thereof, in North Canton, San Diego, Horsham, St. Louis, Irvine, Atlanta, Brentwood, and Phoenix based on projected sublease rental income and estimated sublease commencement dates.

Business Combinations

Business Combinations	12 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Business Combinations	7. Business Combinations On October 4, 2019, we completed the acquisition of Topaz Information Systems, LLC ("Topaz") pursuant to the Membership Interest Purchase Agreement, dated October 4, 2019. Topaz was based in Phoenix, AZ and provides healthcare solutions to behavioral health and social services organizations that utilize the NextGen platform. Its extensive clinical content and domain expertise have been instrumental in our ability to compete and win. By combining our companies, we are positioned to provide the platform and domain expertise to deliver integrated and collaborative care in a re-energized behavioral health market. The final purchase price of Topaz is summarized in the table below. On December 6, 2019, we completed the acquisition of Medfusion, Inc. (“Medfusion”) pursuant to the Agreement and Plan of Merger, dated November 12, 2019. Headquartered in Cary, North Carolina, Medfusio n provides software application services which enable healthcare providers to better serve its patients through enhanced communication. Services are delivered through a standard web browser and typically include features such as appointment scheduling, patient preregistration, prescription renewal, ask a clinician, website development, patient payment, and online bill payment. Medfusion is a portal and patient pay player with a focu On December 17, 2019, we completed the acquisition of OTTO Health, LLC (“OTTO”), pursuant to the Agreement and Plan of Merger, dated December 11, 2019. Based in Boulder, Colorado, OTTO is a telehealth platform that seamlessly integrates into EHR systems allowing providers to have video visits with their patients as part of their normal workflows. OTTO partners closely with EHR providers to create a streamlined user experience, while maintaining the EHR/PM system as the single source of truth. We accounted for the acquisitions as business combinations using the acquisition method of accounting. The purchase price allocation of the Topaz, Medfusion, and OTTO acquisitions are deemed to be final. The purchase price was allocated to the tangible and intangible assets a cquired and liabilities assumed based on their estimated fair values as of the acquisition date. D purchase price Goodwill represents the excess of the purchase price over the net identifiable assets acquired and liabilities assumed. Goodwill primarily represents, among other factors, the value of synergies expected to be realized and the assemblage of all assets that enable us to create new client relationships, neither of which qualify as separate amortizable intangible assets. Goodwill arising from the acquisitions of OTTO and Topaz are considered deductible for tax purposes, and goodwill arising from the acquisition of Medfusion is not deductible for tax purposes. The final purchase price for the acquisitions of Topaz, Medfusion, and OTTO are summarized as follows: Topaz Medfusion OTTO Purchase Price Purchase Price Purchase Price Initial purchase price $ 8,000 $ 43,000 $ 22,000 Settlement of pre-existing net liabilities 1,671 24 19 Fair value of contingent consideration 1,850 — — Working capital adjustment (344 ) (148 ) (59 ) Total purchase price $ 11,177 $ 42,876 $ 21,960 Fair value of the net tangible assets acquired and liabilities assumed: Acquired cash and cash equivalents $ 353 $ 204 $ 102 Accounts receivable 1,528 986 51 Prepaid expense and other assets 139 387 79 Equipment and improvements 194 434 — Operating lease assets 534 — — Accounts payable (224 ) (1,360 ) (2 ) Accrued compensation and related benefits (155 ) (270 ) (123 ) Contract liabilities (370 ) (529 ) (11 ) Deferred income tax liability — (953 ) — Operating lease liabilities (240 ) — — Operating lease liabilities, net of current (360 ) — — Other liabilities (102 ) (443 ) (26 ) Total net tangible assets acquired and liabilities assumed 1,297 (1,544 ) 70 Fair value of identifiable intangible assets acquired: Goodwill 5,380 23,570 19,490 Software technology 4,500 13,800 2,400 Customer relationships — 6,800 — Trade names — 250 — Total identifiable intangible assets acquired 9,880 44,420 21,890 Total purchase price $ 11,177 $ 42,876 $ 21,960 Under the provisions of the Topaz acquisition, we may pay up to an additional $2,000 of cash contingent consideration in the form of an earnout, subject to Topaz achieving certain operational targets through April 2021. The initial fair value of contingent consideration of $1,850 reflects an estimated earnout payment of $2,000 on a present value basis and was estimated based on the weighted probability of achieving the operational targets utilizing assumptions and inputs from Topaz management. The software technology intangible assets acquired from Topaz will be amortized over 6 years. In connection with the Medfusion acquisition, the acquired software technology intangible assets will be amortized over 6 years, acquired customer relationships intangible assets will be amortized over 10 years, and acquired trade names intangible assets will be amortized over 5 years. The weighted average amortization period for the acquired Medfusion intangible assets is 7.3 years. The software technology intangible assets acquired from OTTO will be amortized over 7 years. The revenues, earnings, and pro forma effects of the Topaz, Medfusion, and OTTO acquisitions are not, and would not have been, material to our results of operations, individually and in aggregate, and the disclosure of such information is impracticable as we have already integrated certain aspects of each acquisition within our overall operations and expect for each acquisition to be fully integrated within a short timeframe.

Goodwill

Goodwill	12 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	8. During the quarter ended June 30, 2020, we elected to bypass the optional qualitative step of the goodwill impairment assessment and proceed directly with the quantitative step, whereby we compared the fair value of our single reporting unit with its carrying amount. The results of the goodwill impairment assessment indicated that the fair value of our reporting unit exceeded its net carrying amount by a significant amount, indicating that no goodwill impairment existed as of the annual test dates ended March 31, 2021 and March 31, 2020. We also did not identify any events or circumstances that would require an interim goodwill impairment test. We determined the fair value of our reporting unit utilizing the average of two valuation methods, consisting of the income approach (based upon estimates of future discounted cash flows for the reporting unit) and a market comparable approach (based upon valuation multiples of companies that operate in similar industries with similar operating characteristics). The cash flows used to determine fair value under the income approach required significant judgments and represent Management's best estimates of projected operating results, terminal and long-term growth rates of our business, useful life over which cash flows will occur, and our weighted average cost of capital, that are dependent on a number of significant assumptions based on historical experience, expectations of future performance, and the expected macroeconomic environment, which are subject to change given the inherent uncertainty in predicting future results. We also considered our stock price and market capitalization as a corroborative step in assessing the reasonableness of the fair values estimated for the reporting unit as part of the goodwill impairment assessment. The carrying amount of goodwill as of March 31, 2021 was $267,212. The carrying amount of goodwill as of March 31, 2020 was $267,165.

Intangible Assets

Intangible Assets	12 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	9. Our definite-lived intangible assets, other than capitalized software development costs, are summarized as follows: March 31, 2021 Customer Relationships Trade Names Software Technology Total Gross carrying amount $ 39,200 $ 250 $ 91,500 $ 130,950 Accumulated amortization (26,349 ) (67 ) (67,834 ) (94,250 ) Net intangible assets $ 12,851 $ 183 $ 23,666 $ 36,700 March 31, 2020 Customer Relationships Trade Names Software Technology Total Gross carrying amount $ 39,200 $ 250 $ 113,700 $ 153,150 Accumulated amortization (21,951 ) (17 ) (73,373 ) (95,341 ) Net intangible assets $ 17,249 $ 233 $ 40,327 $ 57,809 Amortization expense related to customer relationships and trade names recorded as operating expenses in the consolidated statements of net income and comprehensive income was $4,449, $4,143, and $4,344 for the years ended March 31, 2021, 2020 and 2019, respectively. Amortization expense related to software technology recorded as cost of revenue was $16,660, $18,393, and $17,152 for the years ended March 31, 2021, 2020, and 2019, respectively. The following table summarizes the remaining estimated amortization of definite-lived intangible assets as of March 31, 2021: Estimated Remaining Amortization Expense Operating Expense Cost of Revenue Total For the year ended March 31, 2022 $ 3,525 $ 8,873 $ 12,398 2023 2,820 5,154 7,974 2024 2,279 3,573 5,852 2025 1,846 3,573 5,419 2026 1,377 2,251 3,628 2027 and beyond 1,187 242 1,429 Total $ 13,034 $ 23,666 $ 36,700

Capitalized Software Costs

Capitalized Software Costs	12 Months Ended
	Mar. 31, 2021
Research And Development [Abstract]
Capitalized Software Costs	10. Capitalized Software Costs Our capitalized software costs are summarized as follows: March 31, 2021 March 31, 2020 Gross carrying amount $ 96,908 $ 75,212 Accumulated amortization (55,434 ) (38,208 ) Net capitalized software costs $ 41,474 $ 37,004 During the year ended March 31, 2020, we recorded $3,198 of impairments related to the write down of previously capitalized software development costs for certain technology that will no longer be utilized in any future software solutions. During the year ended March 31, 2019, we The following table presents the remaining estimated amortization of capitalized software costs as of March 31, 2021. The estimated amortization is comprised of (i) amortization of released products and (ii) the expected amortization for products that are not yet available for sale based on their estimated economic lives and projected general release dates. For the year ended March 31, 2022 $ 24,200 2023 11,800 2024 5,400 2025 74 Total $ 41,474

Line of Credit

Line of Credit	12 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Line of Credit	11. Line of Credit On March 12, 2021, we entered into a $300 million second amended and restated revolving credit agreement (the “Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “Administrative Agent”), U.S. Bank National Association and Bank of the West, as co-syndication agents, and certain other agents and lenders. The Credit Agreement replaces our prior $300 million amended and restated revolving credit agreement, originally entered into on January 4, 2016 and amended on March 29, 2018 (“Original Credit Agreement”). The Credit Agreement is secured by substantially all of our existing and future property and our material domestic subsidiaries. The Credit Agreement provides a subfacility of up to $10 million for letters of credit and a subfacility of up to $10 million for swing-line loans. The Credit Agreement also provides us with the ability to obtain up to $150 million in the aggregate of additional revolving credit commitments and/or term loans thereunder (i.e., in excess of $300 million) upon satisfaction of certain conditions, including receipt of commitments from new or existing lenders to provide such additional revolving credit commitments and/or term loans. The Credit Agreement matures on March 12, 2026 and the full balance of the revolving loans and all other obligations under the Credit Agreement must be paid at that time. In addition, we are required to prepay the revolving loan balance if at any time the aggregate principal amount outstanding under the Credit Agreement exceeds the aggregate commitments thereunder. The revolving loans under the Credit Agreement bear interest at either, at our option, (a) for base rate loans, a base rate based on the highest of (i) 1%, (ii) the “prime rate” quoted in the Wall Street Journal for the United States of America, (iii) the overnight bank funding rate (not to be less than zero) as determined by the Federal Reserve Bank of New York plus 0.50% or (iv) the LIBOR-based rate for one month Eurodollar deposits plus 1%, and (b) for Eurodollar loans, the LIBOR-based rate for one, two, three or six months (as selected by us) Eurodollar deposits plus, in each case, an applicable margin based on our net leverage ratio from time to time, ranging from 0.50% to 1.75% for base rate loans, and from 1.50% to 2.75% for Eurodollar loans. The revolving loans are subject to customary representations, warranties and ongoing affirmative and negative covenants and agreements. The negative covenants include, among other things, limitations on indebtedness, liens, asset sales, mergers and acquisitions, investments, transactions with affiliates, dividends and other restricted payments, payment of subordinated indebtedness and convertible debt and amendments to subordinated indebtedness documents and sale and leaseback transactions of ours or any of our subsidiaries. The Credit Agreement also requires us to maintain (1) a maximum net leverage ratio of 3.75 to 1.00 and (2) a minimum interest coverage ratio of 3.50 to 1.00 at the end of each fiscal quarter through the term of the loan. The revolving loans under the Credit Agreement will be available for letters of credit, permitted acquisitions, working capital and general corporate purposes. We were in compliance with all financial and non-financial covenants under the Credit Agreement as of March 31, 2021. As of March 31, 202 1 , we had no outstanding loans and $ 300,000 of unused credit under the Credit Agreement. As of March 31, 20 20 , we had $ 129,000 in outstanding loans and $ 171,000 of unused credit under the Original Credit Agreement . The interest rate as of March 31, 2020 and w as approximately 2.3 %. During the years ended March 31, 2021, 2020, and 2019, we recorded $2,541, $1,274, and $2,055 of interest expense (excluding amortization of deferred debt issuance costs) Costs incurred in connection with securing the Credit Agreement, including fees paid to legal advisors and third parties, are deferred and amortized to interest expense over the term of the Credit Agreement. Deferred debt issuance costs are reported as a component of other assets on the consolidated balance sheets. As of March 31, 2021, total unamortized debt issuance costs were $2,521, which includes $1,423 of additional costs related to the Credit Agreement, and net of $326 unamortized debt issuance costs that were written off in connection with amending the Original Credit Agreement. As of March 31, 2020, total unamortized debt issuance costs were $2,124. During the years ended March 31, 2021, 2020, and 2019, we recorded $1,026, $710, and $710, respectively, in amortization of deferred debt issuance costs, including amounts written off in the year ended March 31, 2021.

Composition of Certain Financia

Composition of Certain Financial Statement Captions	12 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Composition of Certain Financial Statement Captions	12. Composition of Certain Financial Statement Captions Cash, cash equivalents, and restricted cash are summarized as follows: March 31, 2021 March 31, 2020 Cash and cash equivalents $ 73,295 $ 138,012 Restricted cash and cash equivalents 5,280 2,307 Cash, cash equivalents, and restricted cash $ 78,575 $ 140,319 Prepaid expenses and other current assets are summarized as follows: March 31, 2021 March 31, 2020 Prepaid expenses $ 20,679 $ 18,025 Capitalized commissions costs 9,399 7,053 Other current assets 1,204 1,227 Prepaid expenses and other current assets $ 31,282 $ 26,305 Equipment and improvements are summarized as follows: March 31, 2021 March 31, 2020 Computer equipment and software $ 35,244 $ 34,756 Internal-use software 18,174 17,796 Furniture and fixtures 11,555 12,477 Leasehold improvements 14,418 13,681 Equipment and improvements, gross 79,391 78,710 Accumulated depreciation and amortization (64,852 ) (58,874 ) Equipment and improvements, net $ 14,539 $ 19,836 Other assets are summarized as follows: March 31, 2021 March 31, 2020 Capitalized commission costs $ 19,104 $ 17,537 Deposits 5,505 6,074 Debt issuance costs 2,521 2,124 Other noncurrent assets 9,891 7,921 Other assets $ 37,021 $ 33,656 Accrued compensation and related benefits are summarized as follows: March 31, 2021 March 31, 2020 Accrued bonus $ 29,382 $ 10,396 Accrued vacation 12,038 10,469 Accrued commissions 4,628 2,087 Deferred payroll taxes 3,817 — Accrued payroll and other 509 840 Accrued compensation and related benefits $ 50,374 $ 23,792 Other current and noncurrent liabilities are summarized as follows: March 31, 2021 March 31, 2020 Sales returns reserves and other customer liabilities $ 9,449 $ 6,395 Accrued legal expense 6,302 2,119 Accrued hosting costs 6,158 4,652 Care services liabilities 5,280 2,307 Accrued employee benefits and withholdings 4,649 3,002 Customer credit balances and deposits 4,638 4,260 Accrued royalties 3,125 3,113 Accrued consulting and outside services 3,002 2,520 Accrued outsourcing costs 2,266 2,378 Accrued EDI expense 2,020 3,511 Accrued self insurance expense 1,737 2,054 Accrued taxes payable 586 1,222 Contingent consideration related to acquisitions 533 — Other accrued expenses 2,954 3,819 Other current liabilities $ 52,699 $ 41,352 Deferred payroll taxes $ 3,817 $ — Uncertain tax positions 3,175 1,203 Contingent consideration related to acquisitions — 1,900 Other liabilities 144 178 Other noncurrent liabilities $ 7,136 $ 3,281

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The provision for (benefit of) income taxes consists of the following components: Fiscal Year Ended March 31, 2021 2020 2019 Current: Federal taxes $ 6,562 $ 408 $ 1,159 State taxes 1,226 858 (238 ) Foreign taxes 826 874 744 Total current taxes 8,614 2,140 1,665 Deferred: Federal taxes $ (6,053 ) $ (3,578 ) $ 3,752 State taxes (2,068 ) (1,682 ) (428 ) Foreign taxes (733 ) (119 ) (195 ) Total deferred taxes (8,854 ) (5,379 ) 3,129 Provision for (benefit of) income taxes $ (240 ) $ (3,239 ) $ 4,794 The provision for (benefit of) income taxes differs from the amount computed at the federal statutory rate as follows: Fiscal Year Ended March 31, 2021 2020 2019 Tax expense at United States federal statutory rate (1) $ 1,948 $ 895 $ 6,150 Items affecting federal income tax rate: Research and development tax credits (3,449 ) (4,705 ) (4,647 ) Impact of foreign operations (1,203 ) (683 ) (304 ) Impact of deferred adjustments (251 ) 159 132 Impact of audit settlements (56 ) (61 ) 967 Return to provision true-ups (15 ) (1,868 ) (149 ) Impact of amended returns (9 ) 67 391 Acquisition expenses — 229 (2 ) Foreign transition tax - Tax Reform — — 210 Revaluation of deferred tax balances - Tax Reform — — 231 Impact of uncertain tax positions 278 1,062 375 Non-deductible expenses 517 903 140 Impact of valuation allowance 563 (49 ) (33 ) State income taxes 572 687 1,502 Compensation 865 125 (169 ) Provision for (benefit of) income taxes $ (240 ) $ (3,239 ) $ 4,794 (1 ) 21.0% The net deferred tax assets and liabilities in the accompanying consolidated balance sheets consist of the following: March 31, 2021 March 31, 2020 Deferred tax assets: Compensation and benefits $ 19,541 $ 11,966 Deferred revenue 8,325 10,546 Research and development credit 7,706 9,643 Net operating losses 7,652 8,812 Operating lease liabilities 6,204 11,430 Foreign deferred taxes 2,306 1,574 Allowance for doubtful accounts 1,819 1,819 Accrued legal settlement 905 — Total deferred tax assets 54,458 55,790 Deferred tax liabilities: Intangibles assets $ (9,451 ) $ (12,477 ) Prepaid expense (9,396 ) (7,842 ) Capitalized software (4,659 ) (9,931 ) Operating right-of-use assets (3,003 ) (6,667 ) Accelerated depreciation (1,339 ) (1,405 ) Other (611 ) (145 ) Accounts receivable (510 ) (1,251 ) Total deferred tax liabilities (28,969 ) (39,718 ) Valuation allowance (6,015 ) (5,452 ) Deferred tax assets, net $ 19,474 $ 10,620 The deferred tax assets and liabilities have been shown net in the accompanying consolidated balance sheets as noncurrent. As of March 31, 2021 and 2020, we had federal net operating loss (“NOL”) carryforwards of $18,748 and $24,216, respectively. The federal NOL carryforwards were inherited in connection with our acquisitions of HealthFusion in January 2016, Gennius in March 2015, Entrada in April 2017, EagleDream in August 2017, and Medfusion in December 2019. The NOL carryforwards expire in various amounts starting in fiscal 2030 for both federal and state tax purposes. As of March 31, 2021, we had state NOL carryforwards of approximately $3,715 (tax effected), related to the HealthFusion, Entrada, EagleDream, and Medfusion acquisitions state NOL tax attribute. The utilization of the federal NOL carryforwards is subject to limitations under the rules regarding changes in stock ownership as determined by the Internal Revenue Code. As of March 31, 2021 and 2020, the research and development tax credit carryforward available to offset future federal and state taxes was $8,574 and $12,399, respectively. The federal credits include credits inherited in connection with our acquisition of Medfusion in December 2019. The credits expire in various amounts starting in fiscal 2034. We expect to receive the full benefit of the deferred tax assets recorded with the exception of certain state credits and NOL carryforwards for which we have recorded a valuation allowance. Notwithstanding the U.S. taxation of the deemed repatriated foreign earnings as a result of the one-time Transition Tax, we intend to continue investing these earnings indefinitely outside of the U.S. If we determine that all or a portion of our foreign earnings are no longer to be indefinitely reinvested, we may be subject to additional foreign withholding taxes and state income taxes in the U.S. beyond the Tax Reform’s one-time Transition Tax. In the event that we distribute the foreign earnings to the U.S., we will incur and record foreign withholding related taxes and U.S. state taxes of approximately $3,400 and $600, respectively. The Taxation Laws (Amendment) Act, 2019 was enacted on December 12, 2019 to lower corporate tax rates in India. We opted not to elect for the reduced tax rate for various factors for the year ended March 31, 2021 and 2020. Uncertain tax positions A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is recorded within other noncurrent liabilities in our consolidated balance sheet, is as follows: Balance as of March 31, 2019 $ 2,894 Additions for prior year tax positions 1,372 Additions for current year tax positions 781 Reductions for prior year tax positions (855 ) Balance as of March 31, 2020 4,192 Additions for prior year tax positions 220 Additions for current year tax positions 635 Reductions for prior year tax positions (621 ) Balance as of March 31, 2021 $ 4,426 During the year ended March 31, 2021, we recorded additional net liabilities of $234 related to various federal and state tax planning benefits recorded in the current year for current and prior year tax positions. If recognized, the total amount of unrecognized tax benefit that would decrease the income tax provision is $4,426. Our practice is to recognize interest related to income tax matters as interest expense in the consolidated statements of net income and comprehensive income. We had approximately $88 and $174 of accrued interest related to income tax matters as of March 31, 2021 and 2020, respectively. We recognized interest income of $85, interest income of $35, and interest expense of $19 in the years ended March 31, 2021, 2020 and 2019, respectively, related to income tax matters in the consolidated statements of net income and comprehensive income. No penalties related to income tax matters were accrued or recognized in our consolidated financial statements for all periods presented. We are no longer subject to U.S. federal income tax examinations for tax years before fiscal year ended 2017. With a few exceptions, we are no longer subject to state or local income tax examinations for tax years before fiscal year ended 2016. We do not anticipate that total unrecognized tax benefits will significantly change due to the settlement of audits or the expiration of statute of limitations within the next twelve months. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) and the Consolidated Appropriations Act, 2021 (“Stimulus Bill”), signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Additionally, several state and foreign jurisdictions have enacted additional legislation and or comply with federal changes. We have considered the applicable tax law changes and recognized the impact in our income tax provision, as applicable.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Mar. 31, 2021
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	14. Employee Benefit Plans We provide a 401(k) plan to substantially all of our employees. Participating employees may defer up to the Internal Revenue Service limit per year based on the Internal Revenue Code. The annual contribution is determined by a formula set by our Board of Directors ("Board") and may include matching and/or discretionary contributions. The amount of the Company match is discretionary and subject to change. The retirement plans may be amended or discontinued at the discretion of the Board. Net contributions of $4,625, $4,658 and $5,206 were made by the Company to the 401(k) plan for the years ended March 31, 2021, 2020, and 2019, respectively. We have a deferred compensation plan (the “Deferral Plan”) for the benefit of those employees who qualify. Participating employees may defer up to 75% of their salary and 100% of their annual bonus for a Deferral Plan year. In addition, we may, but are not required to, make contributions into the Deferral Plan on behalf of participating employees, and the amount of the Company match is discretionary and subject to change. Each employee's deferrals together with earnings thereon are accrued as part of our long-term liabilities. Investment decisions are made by each participating employee from a family of mutual funds. The deferred compensation liability was $6,620 and $5,300 at March 31, 2021 and 2020, respectively. To offset this liability, we have purchased life insurance policies on some of the participants. The Company is the owner and beneficiary of the policies and the cash values are intended to produce cash needed to help make the benefit payments to employees when they retire or otherwise leave the Company. We intend to hold the life insurance policy until the death of the plan participant. The cash surrender value of the life insurance policies for deferred compensation was $ 8,126 and $ 7,029 at March 31, 202 1 and 20 20 , respectively. The values of the life insurance policies and our related obligations are included on the accompanying consolidated balance sheets in long-term other assets and long-term deferred compensation, respectively. We made contributions of $ 79 , $ 74 and $ 71 to the Deferral Plan for the years ended March 31, 202 1 , 20 20 , and 201 9 , respectively.

Share-Based Awards

Share-Based Awards	12 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Awards	15. Share-Based Awards Employee Stock Option and Incentive Plans In October 2005, our shareholders approved a stock option and incentive plan (the “2005 Plan”) under which 4,800,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock, unrestricted stock, restricted stock units, performance shares, performance units (including performance options) and other share-based awards. The 2005 Plan provides that our employees and directors may, at the discretion of the Board or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the 2005 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the 2005 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the 2005 Plan, awards under the 2005 Plan will fully vest under certain circumstances. The 2005 Plan expired on May 25, 2015. As of March 31, 2021, there were 142,220 outstanding options under the 2005 Plan. In August 2015, our shareholders approved a stock option and incentive plan (the “2015 Plan”) under which 11,500,000 shares of common stock were reserved for the issuance of awards, including incentive stock options and non-qualified stock options, stock appreciation rights, restricted stock awards and restricted stock unit awards, performance stock awards and other share-based awards. In August 2017, our shareholders approved an amendment to the 2015 Equity, (the “Amended 2015 Plan”), to, among other items, increase the number of shares of common stock reserved for issuance thereunder by 6,000,000, which was further amended in August 2019 as approved by our shareholders, to, among other items, increase the number of shares of common stock reserved for issuance thereunder by an additional 3,575,000. The Amended 2015 Plan provides that our employees and directors may, at the discretion of the Board or a duly designated compensation committee, be granted certain share-based awards. In the case of option awards granted under the Amended 2015 Plan, the exercise price of each option is determined based on the date of grant and expire no later than 10 years from the date of grant. Awards granted pursuant to the Amended 2015 Plan are subject to the vesting schedule or performance metrics set forth in the agreements pursuant to which they are granted. Upon a change of control of our Company, as such term is defined in the Amended 2015 Plan, awards under the Amended 2015 Plan will fully vest under certain circumstances. As of March 31, 2021, there were 2,648,864 outstanding options, 2,263,569 outstanding shares of restricted stock awards, certain outstanding performance stock unit awards as described further below, and 1,538,544 shares available for future grant under the Amended 2015 Plan. The following table summarizes the stock option transactions during the years ended March 31, 2021, 2020, and 2019: Weighted- Weighted- Average Average Aggregate Exercise Remaining Intrinsic Number of Price Contractual Value Shares per Share Life (years) (in thousands) Outstanding, March 31, 2018 3,670,170 $ 15.51 6.2 $ 766 Granted 326,130 16.40 6.8 Exercised (375,645 ) 15.49 4.7 1,589 Forfeited/Canceled (451,730 ) 18.00 4.9 Expired (2,400 ) 28.15 Outstanding, March 31, 2019 3,166,525 $ 15.36 5.5 $ 7,040 Exercised (55,325 ) 15.87 4.3 138 Forfeited/Canceled (75,450 ) 23.38 1.5 Expired (34,400 ) 43.04 Outstanding, March 31, 2020 3,001,350 $ 14.83 4.7 $ — Exercised (116,916 ) 16.21 3.3 303 Forfeited/Canceled (47,350 ) 18.58 3.7 Expired (46,000 ) 29.17 Outstanding, March 31, 2021 2,791,084 $ 14.47 3.7 $ 10,303 Vested and expected to vest, March 31, 2021 2,715,933 $ 14.45 3.7 $ 10,075 Exercisable, March 31, 2021 2,331,745 $ 14.33 3.6 $ 8,910 Share-based compensation expense related to stock options was $2,536, $3,826, and $3,936 for the years ended March 31, 2021, 2020, and 2019, respectively. There were no stock options granted during the years ended March 31, 2021 and 2020. During the year ended March 31, 2019, we granted total stock options of 326,130, to purchase shares of common stock under the Amended 2015 Plan at an exercise price equal to the market price of our common stock on the date of grant, as summarized below. Option Grant Date Number of Shares Exercise Price Vesting Terms (1) Expiration May 30, 2018 241,130 $ 16.83 Four Years June 1, 2026 August 3, 2018 60,000 $ 21.27 Four Years August 3, 2026 November 2, 2018 25,000 $ 15.09 Four Years November 2, 2026 Fiscal year 2019 grants 326,130 (1) Unless otherwise indicated, options vest in equal annual installments on each grant anniversary date commencing one year following the date of grant We utilized the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions: Year Ended March 31, 2019 Expected term 6.1 - 6.3 years Expected volatility 34.6% - 36.8% Expected dividends 0.0% Risk-free rate 2.8% - 3.1% The weighted-average grant date fair value of stock options granted during the year ended March 31, 2019 was $7.18 per share. Non-vested stock option award activity during the years ended March 31, 2021, 2020, and 2019 is summarized as follows: Weighted- Average Grant-Date Number of Fair Value Shares per Share Outstanding, March 31, 2018 2,657,005 $ 5.18 Granted 326,130 7.18 Vested (778,900 ) 5.12 Forfeited/Canceled (358,380 ) 5.36 Outstanding, March 31, 2019 1,845,855 $ 5.52 Vested (745,033 ) 5.29 Forfeited/Canceled (9,150 ) 6.42 Outstanding, March 31, 2020 1,091,672 $ 5.67 Vested (605,433 ) 5.40 Forfeited/Canceled (26,900 ) 6.80 Outstanding, March 31, 2021 459,339 $ 5.96 As of March 31, 2021, $1,473 of total unrecognized compensation costs related to stock options is expected to be recognized over a weighted-average period of 0.7 years. This amount does not include the cost of new options that may be granted in future periods or any changes in our forfeiture percentage. The total fair value of options vested during the years ended March 31, 2021, 2020, and 2019 was $3,272, $3,940, and $3,985, respectively. Restricted Stock Awards Restricted stock awards activity during the years ended March 31, 2021, 2020, and 2019 is summarized as follows: Weighted- Average Grant-Date Number of Fair Value Shares per Share Outstanding, March 31, 2018 1,820,910 $ 14.52 Granted 885,845 18.14 Vested (642,695 ) 14.63 Canceled (348,102 ) 14.79 Outstanding, March 31, 2019 1,715,958 $ 16.29 Granted 1,529,831 16.93 Vested (764,290 ) 16.05 Canceled (168,719 ) 17.06 Outstanding, March 31, 2020 2,312,780 $ 16.74 Granted 1,222,863 12.04 Vested (1,053,792 ) 16.22 Canceled (218,282 ) 15.30 Outstanding, March 31, 2021 2,263,569 $ 14.58 Share-based compensation expense related to restricted stock awards was $16,371, $14,706, and $10,875 for the years ended March 31, 2021, 2020, and 2019, respectively. The weighted-average grant date fair value for the restricted stock awards was estimated using the market price of the common stock on the date of grant. The fair value of the restricted stock awards is amortized on a straight-line basis over the vesting period, which is generally between one to three years. As of March 31, 2021, $23,277 of total unrecognized compensation costs related to restricted stock awards is expected to be recognized over a weighted-average period of 1.8 years. This amount does not include the cost of new restricted stock awards that may be granted in future periods. Performance Stock Units and Awards On December 29, 2016, the Compensation Committee of the Board granted 123,082 performance stock awards to certain executive officers, of which no shares are currently outstanding. The performance stock awards vested in four equal increments on each of the first four anniversaries of the grant date, subject in each case to the executive officer’s continued service and achievement of certain Company performance goals, including strong stock price performance. Share-based compensation expense related to the performance stock awards was $184 for the year ended March 31, 2021. On October 23, 2018, the Compensation Committee of the Board approved 248,140 performance stock unit awards to be granted to certain executives and non-executive members of the executive leadership team, which vest only in the event certain performance goals are achieved and with continuous service through the date the goals are certified. Approximately 34% of the performance stock units are tied to our cumulative 3-year total shareholder return, 33% are tied to our fiscal year 2021 revenue, and 33% are tied to our fiscal year 2021 adjusted earnings per share goals, each as specifically defined in the equity award agreements. The number of shares to be issued may vary between 50% and 200% of the number of performance stock units depending on performance, and no such shares will be issued if threshold performance is not achieved. The weighted-average grant date fair value of the awards was $17.84 per share, which was estimated using a Monte Carlo-based valuation model for the awards based on total shareholder return and using a probability-adjusted achievement rate combined with the market price of the common stock on the date of grant for the awards based on revenue and earnings per share targets. Share-based compensation expense related to the performance stock unit awards was $458, $123 and $534 for the years ended March 31, 2021, 2020 and 2019, respectively. On December 26, 2019 and January 27, 2020, the Compensation Committee of the Board approved a total of 279,587 performance stock unit awards to be granted to certain executives and non-executive members of the executive leadership team, which vest only in the event certain performance goals are achieved and with continuous service through the date the goals are certified. Approximately 80% of the performance stock units are tied to the Company’s fiscal year 2021 revenue goal and 20% are tied to the Company’s fiscal year 2022 revenue goal. Performance stock unit awards funded for fiscal year 2021 and fiscal year 2022 revenue performance will be modified for cumulative 3-year total shareholder return (“TSR”) on the three-year On October 26, 2020, the Compensation Committee of the Board approved 408,861 performance stock unit awards to be granted to certain executives and non-executive members of the executive leadership team, which vest only in the event certain performance goals are achieved and with continuous service through the date the goals are certified. Approximately 80% of the performance stock units are tied to the Company’s fiscal year 2022 revenue goal and 20% are tied to the Company’s fiscal year 2023 revenue goal. Performance stock unit awards funded for fiscal year 2022 and fiscal year 2023 revenue performance will be modified for cumulative 3-year TSR on the three-year which was estimated using a Monte Carlo-based valuation model for the awards based on total shareholder return and using a probability adjusted achievement rate combined with the market price of the common stock on the date of grant for the awards based on revenue targets. Share-based compensation expense related to the performance stock unit awards was $1,187 for the year ended March 31, 2021. As of March 31, 2021, $9,896 of total estimated unrecognized compensation costs related to performance stock units and awards is expected to be recognized over a weighted-average period of 2.3 years. This amount does not include the cost of new performance stock units and awards that may be granted in future periods. Employee Share Purchase Plan On August 11, 2014, our shareholders approved an Employee Share Purchase Plan (the “Purchase Plan”) under which 4,000,000 shares of common stock were reserved for future grant. The Purchase Plan allows eligible employees to purchase shares through payroll deductions of up to 15% of total base salary at a price equal to 90% of the lower of the fair market values of the shares as of the beginning or the end of the corresponding offering period. Any shares purchased under the Purchase Plan are subject to a six-month holding period. Employees are limited to purchasing no more than 1,500 shares on any single purchase date and no more than $25,000 in total fair market value of shares during any one calendar year. As of March 31, 2021, we have issued 748,828 shares under the Purchase Plan and 3,251,172 shares are available for future issuance. Share-based compensation expense recorded for the employee share purchase plan was $519, $484, and $481 for the years ended March 31, 2021, 2020, and 2019, respectively.

Commitments, Guarantees and Con

Commitments, Guarantees and Contingencies	12 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments, Guarantees and Contingencies	16. Commitments, Guarantees and Contingencies Commitments and Guarantees Our software license agreements include a performance guarantee that our software products will substantially operate as described in the applicable program documentation for a period of 365 days after delivery. To date, we have not incurred any significant costs associated with our performance guarantee or other related warranties and do not expect to incur significant warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties. Certain arrangements also include performance guarantees related to response time, availability for operational use, and other performance-related guarantees. Certain arrangements also include penalties in the form of maintenance credits should the performance of the software fail to meet the performance guarantees. To date, we have not incurred any significant costs associated with these warranties and do not expect to incur significant warranty costs in the future. Therefore, no accrual has been made for potential costs associated with these warranties. We historically have accepted sales returns under limited circumstances. We estimate expected sales returns and other forms of variable consideration considering our customary business practice and contract-specific facts and circumstances, and we consider such estimated potential returns as variable consideration when allocating the transaction price to the extent it is probable that there will not be a significant reversal of cumulative revenue recognized. Our standard sales agreements contain an indemnification provision pursuant to which we shall indemnify, hold harmless, and reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any United States patent, any copyright or other intellectual property infringement claim by any third-party with respect to our software. As we have not incurred any significant costs to defend lawsuits or settle claims related to these indemnification agreements, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these indemnification obligations. Hussein Litigation On October 7, 2013, a complaint was filed against our Company and certain of our officers and directors in the Superior Court of the State of California for the County of Orange, captioned Ahmed D. Hussein v. Sheldon Razin, Steven Plochocki, Quality Systems, Inc. and Does 1-10, inclusive, No. 30-2013-00679600-CU-NP-CJC, by Ahmed Hussein, a former director and significant shareholder of our Company. After the court sustained our demurrer to the initial complaint, Hussein filed an amended complaint on April 25, 2014. The amended complaint generally alleges fraud and deceit, constructive fraud, negligent misrepresentation and breach of fiduciary duty in connection with statements made to our shareholders regarding our financial condition and projected future performance. The amended complaint seeks actual damages, exemplary and punitive damages and costs. Hussein’s breach of fiduciary duty claims were dismissed on demurrer, and we filed an answer and cross-complaint against Hussein, alleging that he breached fiduciary duties owed to the Company. On September 16, 2015, the Court granted summary judgment with respect to Hussein’s remaining claims, dismissing all claims against us. The cross-complaint against Hussein went to trial, but the Court granted judgment in favor of Hussein on our cross-complaint. Final judgment over Hussein’s claims and our cross-claims was entered on January 9, 2018. Hussein appealed the order granting summary judgment over his claims, and we appealed the court’s decision granting Hussein’s motion for judgment on our cross-complaint. On October 8, 2019, the California State Court of Appeal for the Fourth Appellate District, Division Three, reversed the Superior Court’s grant of summary judgment on Hussein’s affirmative claims and affirmed the trial court’s judgement on the Company’s breach of fiduciary duty claims against Hussein. As a result, the case has returned to the trial court for resolution of Hussein’s claims against us. Previously scheduled trial dates have been postponed due to the ongoing pandemic, and a new trial date has been set for July 6, 2021. Separately, Hussein has issued an arbitration demand seeking indemnification for the fees he incurred defending against our cross-complaint. Following briefing and a hearing at the liability phase of the arbitration, the arbitrator held that Hussein is entitled to indemnification for “Expenses” (as that term is defined in Hussein’s indemnification agreement with NextGen) incurred in defense of NextGen’s cross-complaint against him. The arbitrator will determine the quantum of indemnifiable Expenses at a second phase of the arbitration scheduled for June 10, 2021. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this matter. Other Regulatory Matters Commencing in April 2017, we have received requests for documents and information from the United States Attorney's Office for the District of Vermont and other government agencies in connection with an investigation concerning the certification we obtained for our software under the United States Department of Health and Human Services' Electronic Health Record (EHR) Incentive Program. The requests for information relate to, among other things: (a) data used to determine objectives and measures under the Meaningful Use (MU) and the Physician Quality Reporting System (PQRS) programs, (b) EHR software code used in certifying our software and information, and (c) payments provided for the referral of EHR business. We continue to cooperate in this investigation. Requests and investigations of this nature may lead to future requests for information and ultimately the assertion of claims or the commencement of legal proceedings against us, as well as other material liabilities. In addition, our responses to these and any future requests require time and effort, which can result in additional cost to us. At this time, we are unable to estimate the probability or the amount of liability, if any, related to this matter. Given the highly-regulated nature of our industry, we may, from time to time, be subject to subpoenas, requests for information, or investigations from various government agencies. It is our practice to respond to such matters in a cooperative, thorough and timely manner . At this time, we are unable to estimate the probability or the amount of liability, if any, related to this matter.

Restructuring Plan

Restructuring Plan	12 Months Ended
	Mar. 31, 2021
Restructuring Costs [Abstract]
Restructuring Plan	17. Restructuring Plan In May 2020, we announced a decision to execute a reduction in our workforce of less than 3% as well as other temporary cost reductions in response to the COVID-19 pandemic. We recorded $2,562 of restructuring costs, consisting of payroll-related costs, such as severance, outplacement costs, and continuing healthcare coverage, associated with the involuntary separation of employees pursuant to a one-time benefit arrangement, for the year ended March 31, 2021 within operating expenses in our consolidated statements of net income and comprehensive income. These amounts were accrued when it was probable that the benefits would be paid, and the amounts were reasonably estimable. The payroll-related costs were substantially paid as of March 31, 2021. In June 2019, we implemented a business restructuring plan as part of our continued efforts to preserve and grow the value of the Company through client-focused innovations while reducing our cost structure. As part of the restructuring, we reduced our total workforce by approximately 4% primarily within the research and development function and intend to expand on our research and development resources in India. We recorded $2,505 of restructuring costs in the year ended March 31, 2020 within operating expenses in our consolidated statements of comprehensive income. The restructuring costs consisted primarily of payroll-related costs, such as severance, outplacement costs, and continuing healthcare coverage, associated with the involuntary separation of employees pursuant to a one-time benefit arrangement. These amounts were accrued when it was probable that the benefits would be paid, and the amounts were reasonably estimable. The payroll-related costs were substantially paid as of March 31, 2020. During the year ended March 31, 2019, we recorded $640 of restructuring costs related to adjustments to the estimated fair value of remaining lease obligations for vacated properties associated with our prior restructuring plan. The restructuring costs were comprised of facilities-related costs associated with accruals for the remaining lease obligations at certain locations, including Solana Beach, St. Louis, and a portion of Horsham with contractual lease terms ending between January 2018 and September 2023. We estimated the remaining lease obligations at fair value as of the cease-use date for each location based on the future contractual lease obligations, reduced by projected sublease rentals that could be reasonably obtained for the locations after a period of marketing, and adjusted for the effect deferred rents that have been recognized under the lease. The effect of discounting future cash flows using a credit-adjusted risk free rate was not significant. Sublease income and commencement dates were estimated based on data available from rental activity in the local markets. As of March 31, 2019, the remaining lease obligation, net of estimated projected sublease rentals, was $1,762.

Schedule II Valuation and Quali

Schedule II Valuation and Qualifying Accounts	12 Months Ended
	Mar. 31, 2021
Valuation And Qualifying Accounts [Abstract]
Schedule II Valuation and Qualifying Accounts	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS Sales Return Reserve (in thousands) For the year ended Balance at Beginning of Year Additions Charged Against Revenue Deductions Balance at End of Year March 31, 2021 $ 4,191 $ 6,595 $ (7,193 ) $ 3,593 March 31, 2020 $ 4,759 $ 7,094 $ (7,662 ) $ 4,191 March 31, 2019 $ 5,520 $ 4,969 $ (5,730 ) $ 4,759 Allowance for Doubtful Accounts (in thousands) For the year ended Balance at Beginning of Year Additions Charged to Costs and Expenses Deductions Balance at End of Year March 31, 2021 $ 3,549 $ 2,834 $ (2,178 ) $ 4,205 March 31, 2020 $ 6,054 $ 3,367 $ (5,872 ) $ 3,549 March 31, 2019 $ 3,876 $ 5,644 $ (3,466 ) $ 6,054 Valuation Allowance for Deferred Taxes (in thousands) For the year ended Balance at Beginning of Year Additions Charged Costs and Expenses Acquisition Related Additions Deductions Balance at End of March 31, 2021 $ 5,452 $ 877 $ — $ (314 ) $ 6,015 March 31, 2020 $ 3,563 $ 327 $ 1,590 $ (28 ) $ 5,452 March 31, 2019 $ 2,893 $ 708 $ — $ (38 ) $ 3,563

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business NextGen Healthcare is a leading provider of software and services that empower ambulatory healthcare practices to manage the risk and complexity of delivering care in the rapidly evolving U.S. healthcare system. Our combination of technological breadth, depth and domain expertise makes us a preferred solution provider and trusted advisor for our clients. In addition to highly configurable core clinical and financial capabilities, our portfolio includes tightly integrated solutions that deliver on ambulatory healthcare imperatives including: population health, care management, patient outreach, telemedicine, and nationwide clinical information exchange. We serve clients across all 50 states. Over 100,000 providers use NextGen Healthcare solutions to deliver care in nearly every medical specialty in a wide variety of practice models including accountable care organizations (“ACOs”), independent physician associations (“IPAs”), managed service organizations (“MSOs”), Veterans Service Organizations (“VSOs”), and Dental Service Organizations (“DSOs”). Our clients include some of the largest and most progressive multi-specialty groups in the country. With the addition of behavioral health to our medical and oral health capabilities, we continue to extend our share not only in Federally Qualified Health Centers (“FQHCs”), but also in the growing integrated care market. NextGen Healthcare has historically enhanced our offering through both organic and inorganic activities. In October 2015, we divested our former Hospital Solutions division to focus exclusively on the ambulatory marketplace. In January 2016, we acquired HealthFusion Holdings, Inc. and its cloud-based electronic health record and practice management solution. In April 2017, we acquired Entrada, Inc. and its cloud-based, mobile platform for clinical documentation and collaboration. In August 2017, we acquired EagleDream Health, Inc. and its cloud-based population health analytics solution. In January 2018, we acquired Inforth Technologies for its specialty-focused clinical content. In October 2019, we acquired Topaz Information Systems, LLC for its behavioral health solutions. In December 2019, we acquired Medfusion, Inc. for its Patient Experience Platform (i.e., patient portal, self-scheduling, and patient pay) capabilities and OTTO Health, LLC for its integrated virtual care solutions, notably telemedicine. The integration of these acquired technologies has made NextGen Healthcare’s solutions among the most comprehensive in the market. Our company was incorporated in California in 1974. Previously named Quality Systems, Inc., we changed our corporate name to NextGen Healthcare, Inc. in September 2018. Our principal executive offices are located at 3525 Piedmont Rd., NE, Building 6, Suite 700, Atlanta, Georgia, and our principal website is www.nextgen.com. We operate on a fiscal year ending on March 31.
Principles of Consolidation	Principles of Consolidation. The consolidated financial statements include the accounts of NextGen Healthcare, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). Each of the terms “NextGen Healthcare,” “NextGen,” “we,” “us,” or “our” as used herein refers collectively to the Company, unless otherwise stated. All intercompany accounts and transactions have been eliminated.
Business Segments	Business Segments. We operated as one segment for the years ended March 31, 2021 and 2020. The measures evaluated by our chief operating decision maker ("CODM"), consisting of our Chief Executive Officer, to assess company performance and make decisions about the allocation of resources include consolidated revenue and consolidated operating results.
Basis of Presentation	Basis of Presentation. References to amounts in the consolidated financial statement sections are in thousands, except shares and per share data, unless otherwise specified.
Coronavirus Pandemic	Coronavirus Pandemic. In late 2019, the emergence of a novel coronavirus, or COVID-19, was reported and in January 2020, the World Health Organization (“WHO”), declared it a Public Health Emergency of International Concern. In March 2020, the WHO escalated COVID-19 as a pandemic. The extent to which COVID-19 may continue to impact our business and financial results depends on numerous evolving factors including, but not limited to, the magnitude and duration of COVID-19; the impact on our employees; the extent to which it impacts worldwide macroeconomic conditions, including interest rates, employment rates, and health insurance coverage; the speed of the recovery; and governmental and business reactions to the pandemic. We assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 at March 31, 2021, and through the date of this Annual Report on Form 10-K. The accounting matters assessed included, but were not limited to, our allowances for doubtful accounts and the carrying value of goodwill and other long-lived assets. While there was not a material impact to our consolidated financial statements at and for the year-ended March 31, 2021, our future assessment of the magnitude and duration of COVID-19, as well as other factors could result in material impacts to our consolidated financial statements in future reporting periods.
Use of Estimates	Use of Estimates. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), which requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and recording revenue and expenses during the period.
Cash and Cash Equivalents	Cash and Cash Equivalents. Cash and cash equivalents consist primarily of cash and money market funds with original maturities of less than 90 days. At March 31, 2021 and March 31, 2020, we had cash and cash equivalents of $73,295 and $138,012, respectively. We also had cash deposits held at United States banks and financial institutions at March 31, 2021 of which $86,317 was in excess of the Federal Deposit Insurance Corporation insurance limit of $250 per owner. Our cash deposits are exposed to credit loss for amounts in excess of insured limits in the event of nonperformance by the institutions; however, we do not anticipate nonperformance by these institutions. Money market funds in which we hold a portion of our excess cash are invested in very high grade commercial and governmental instruments, and therefore bear low market risk.
Restricted Cash and Cash Equivalents	Restricted Cash and Cash Equivalents. Restricted cash and cash equivalents consist of cash that is being held by the Company acting as an agent for the disbursement of certain state social and care services programs. We record an offsetting liability when we initially receive such cash from the programs. We relieve both restricted cash and cash equivalents and the related liability when amounts are disbursed. We earn an administrative fee based on a percentage of the funds disbursed on behalf of the government social and care service programs.
Reserves on Accounts Receivable	Reserves on Accounts Receivable. We maintain reserves for estimated potential sales returns and uncollectible accounts receivable. Accounts receivable are reported net of uncollectible accounts receivable on our consolidated balance sheets. Our standard contracts generally do not contain provisions for clients to return products or services. However, we historically have accepted sales returns under limited circumstances. We estimate expected sales returns and other forms of variable consideration considering our customary business practice and contract-specific facts and circumstances, and we consider such estimated potential returns as variable consideration when allocating the transaction price to the extent it is probable that there will not be a significant reversal of cumulative revenue recognized. We adopted ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments on April 1, 2020 Allowances for doubtful accounts and other uncollectible accounts receivable related to estimated losses resulting from our clients’ inability to make required payments are established based on our assessment of the collectability of client accounts, including review of our historical experience of bad debt expense and the aging of our accounts receivable balances, net of specifically reserved accounts and amounts billed prior to revenue recognition. Specific reserves are based on our estimate of the probability of collection for certain accounts. As part of our assessment of the adequacy of the allowance for doubtful accounts, we considered a number of factors including, but not limited to, historical credit loss experience and adjustments for certain asset-specific risk characteristics, such as bankruptcy filings, internal assessments of client credit quality, age of the client receivable balances, review of major third-party credit-rating agencies, and evaluation of external factors such as economic conditions, including the potential impacts of the COVID-19 pandemic, that may affect a client’s ability to pay, or other client-specific factors. Accounts are written off as uncollectible only after we have expended extensive collection efforts. Refer to Note 4, “Accounts Receivable” for additional information.
Leases	Leases. We adopted ASU 2016-02, Leases (Topic 842) , and its subsequent amendments (together “ASC 842”) using the cumulative-effect adjustment transition method, which is the additional transition method described within ASU 2018-11, Leases (Topic 842): Targeted Improvements , issued by the FASB in July 2018, which allowed us to apply the new lease standard as of April 1, 2019, rather than the beginning of the earliest period presented. Our leasing arrangements are reflected on the balance sheet as right-of-use assets and liabilities pertaining to the rights and obligations created by the leased assets. We determine whether an arrangement is a lease at inception and classify it as finance or operating. All of our existing material leases are classified as operating leases. Our leases do not contain any residual value guarantees. Right-of-use lease assets and corresponding lease liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since the interest rate implicit in our lease arrangements is not readily determinable, we determine an incremental borrowing rate for each lease based on the approximate interest rate on a collateralized basis with similar remaining terms and payments as of the lease commencement date to determine the present value of future lease payments. Our lease terms may include options to extend or terminate the lease. Currently, it is not reasonably certain that we will exercise those options and therefore, we utilize the initial, noncancelable, lease term to calculate the lease assets and corresponding liabilities for all our leases. We have certain insignificant short-term leases with an initial term of twelve months or less that are not recorded in our consolidated balance sheets. Operating right-of-use lease assets are classified as operating lease assets on our consolidated balance sheets. Our lease agreements generally contain lease and non-lease components. Non-lease components primarily include payments for maintenance and utilities. We have applied the practical expedient to combine fixed payments for non-lease components with our lease payments for all of our leases and account for them together as a single lease component, which increases the amount of our lease assets and corresponding liabilities. Payments under our lease arrangements are primarily fixed, however, certain lease agreements contain variable payments, which are expensed as incurred and not included in the operating lease assets and liabilities. Operating lease costs are recognized on a straight-line basis over the lease term and included as a selling, general and administrative expense in the consolidated statements of net income and comprehensive income. Refer to Note 6, "Leases" for additional information.
Equipment and Improvements	Equipment and Improvements. Equipment and improvements are stated at cost less accumulated depreciation and amortization. Repair and maintenance costs that do not improve service potential or extend economic life are expensed as incurred. Depreciation and amortization of equipment and improvements are recorded over the estimated useful lives of the assets, or the related lease terms if shorter, by the straight-line method. Useful lives generally have the following ranges: • Computer equipment and software - 3 to 5 years • Furniture and fixtures - 3 to 7 years • Leasehold improvements - lesser of lease term or estimated useful life of asset Depreciation expense related to our equipment and improvements was $7,997
Capitalized Software Costs	Capitalized Software Costs. Software development costs, consisting primarily of employee salaries and benefits and certain third party costs, incurred in the development of new software solutions and enhancements to existing software solutions for external sale are expensed as incurred, and reported as net research and development costs in the consolidated statements of net income and comprehensive income, until technological feasibility has been established. After technological feasibility is established, any additional software development costs are capitalized. Amortization of capitalized software is recorded on a straight-line basis over the estimated economic life of the related product, which is typically three years. The total of capitalized software costs incurred in the development of products for external sale are reported as capitalized software costs within our consolidated balance sheets. We also incur costs related to the development of software applications for our internal-use and for the development of software-as-a-service ("SaaS") based solutions sold to our clients. The development costs of our SaaS-based solutions are considered internal-use for accounting purposes. Our internal-use capitalized development costs are stated at cost and amortized on a straight-line basis over the estimated useful lives of the assets, which is typically three years. Application development stage costs generally include costs associated with internal-use software configuration, coding, installation and testing. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Costs of significant upgrades and enhancements that result in additional functionality are also capitalized, whereas costs incurred for maintenance and minor upgrades and enhancements are expensed as incurred. Capitalized software costs for the development of SaaS-based solutions are reported as capitalized software costs within our consolidated balance sheets and capitalized software costs for the development of our internal-use software applications are reported as equipment and improvements within our consolidated balance sheets. We periodically reassess the estimated economic life and the recoverability of our capitalized software costs. If we determine that capitalized amounts are not recoverable based on the expected net cash flows to be generated from sales of the applicable software solutions, the amount by which the unamortized capitalized costs exceed the net realizable value is written off as a charge to earnings. The net realizable value is estimated as the expected future gross revenues from that product reduced by the estimated future costs of completing and disposing of that product, including the costs of performing maintenance and client support required to satisfy our responsibility at the time of sale. In addition to the assessment of net realizable value, we review and adjust the remaining estimated lives of our capitalized software costs, if necessary. We also perform a periodic review of our software solutions and dispose of fully amortized capitalized software costs after such products are determined to no longer be used by our clients.
Business Combinations	Business Combinations. In accordance with the accounting for business combinations, we allocate the purchase price of the acquired business to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The fair values of acquired assets and liabilities assumed represent our best estimate of fair value. The estimated fair value of the acquired tangible and intangible assets and liabilities assumed were determined using multiple valuation approaches depending on the type and nature of tangible or intangible asset acquired or liabilities assumed, including but not limited to the income approach, the excess earnings method and the relief from royalty method approach. The purchase price allocation methodology contains uncertainties as it requires us to make assumptions and to apply judgment to estimate the fair value of acquired assets and liabilities, including, but not limited to, intangible assets, goodwill, deferred revenue, and contingent consideration liabilities. We estimate the fair value of the contingent consideration liabilities, as needed, based on our projection of expected results and the estimated probability of achievement. The process to develop the estimate of fair values in many cases requires the use of significant estimates, assumptions and judgments, including determining the timing and estimates of future cash flows and developing appropriate discount rates. Unanticipated events or circumstances may occur which could affect the accuracy of our fair value estimates, including assumptions regarding industry economic factors and business strategies. We expect to finalize the purchase price allocation as soon as practicable within the measurement period, but not later than one year following the acquisition date. Any adjustments to fair value subsequent to the measurement period are reflected in the consolidated statements of net income and comprehensive income.
Goodwill	Goodwill. Goodwill acquired in a business combination is measured as the excess of the purchase price, or consideration transferred, over the net acquisition date fair values of the assets acquired and the liabilities assumed. Goodwill is not amortized as it has been determined to have an indefinite useful life. We test goodwill for impairment annually during our first fiscal quarter, referred to as the annual test date. We will also test for impairment between annual test dates if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is performed at a reporting-unit level, which is defined as an operating segment or one level below an operating segment (referred to as a component). We operate as one segment and have a single reporting unit. The measures evaluated by our chief operating decision maker ("CODM"), consisting of our Chief Executive Officer, to assess company performance and make decisions about the allocation of resources include consolidated revenue and consolidated operating results. As part of our annual goodwill impairment test, we may elect to first assess qualitative factors to determine whether it is more likely than not that the fair value of our single reporting unit is less than its carrying amount. We assess events or changes in circumstances in totality, including macroeconomic and industry conditions, market and competitive environment, changes in customers or customer mix, cost factors, loss of key personnel, significant changes in legislative environment or other legal factors, changes in the use of our acquired assets, changes in our strategic direction, significant changes in projected future results of operations, changes in the composition or carrying amount of our net assets, and changes in our stock price. Based on our assessment, if we conclude that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, then additional impairment testing is not required. Otherwise, if we determine that a quantitative impairment test should be performed, we then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit with its book value, including goodwill. If the estimated fair value exceeds book value, goodwill is considered not to be impaired and no additional steps are necessary. If, however, the fair value of the reporting unit is less than book value, then an impairment charge is recorded for the difference between the reporting unit’s fair value and carrying amount, not to exceed the carrying amount of the goodwill.
Intangible Assets	Intangible Assets. Intangible assets consist of trade names, customer relationships, and software technology, all of which are associated with our acquisitions. The intangible assets are recorded at fair value and are reported net of accumulated amortization. We currently amortize the intangible assets over periods ranging from 5 to 10 years using a method that reflects the pattern in which the economic benefits of the intangible asset are consumed. We assess the recoverability of intangible assets at least annually or whenever adverse events or changes in circumstances indicate that impairment may have occurred. If the future undiscounted cash flows expected to result from the use of the related assets are less than the carrying value of such assets, impairment is deemed to have occurred and a loss is recognized to reduce the carrying value of the intangible assets to fair value, which is determined by discounting estimated future cash flows. In addition to the impairment assessment, we routinely review the remaining estimated lives of our intangible assets and record adjustments, if deemed necessary.
Long-Lived Assets	Long-Lived Assets. We assess our long-lived assets for potential impairment periodically or whenever adverse events or changes in circumstances indicate that impairment may have occurred. If necessary, recoverability of the assets is evaluated based on the future undiscounted cash flows expected to result from the use of the related assets compared to the carrying value of such assets. If impairment is deemed to have occurred, a loss is recognized to reduce the carrying value of the long-lived assets to fair value, which is determined by discounting the estimated future cash flows. In addition to the impairment assessment, we routinely review the remaining estimated lives of our long-lived assets and record adjustments, if deemed necessary.
Income Taxes	Income Taxes. Income taxes are provided based on current taxable income and the future tax consequences of temporary differences between the basis of assets and liabilities for financial and tax reporting. The deferred income tax assets and liabilities represent the future state and federal tax return consequences of those differences, which will either be taxable or deductible when the assets and liabilities are recovered or settled. Deferred income taxes are also recognized for operating losses that are available to offset future taxable income and tax credits that are available to offset future income taxes. At each reporting period, we assess the realizable value of deferred tax assets based on, among other things, estimates of future taxable income and adjust the related valuation allowance as necessary. We make a number of assumptions and estimates in determining the appropriate amount of expense to record for income taxes. The assumptions and estimates consider the taxing jurisdiction in which we operate as well as current tax regulations. Accruals are established for estimates of tax effects for certain transactions and future projected profitability based on our interpretation of existing facts and circumstances.
Advertising Costs	Advertising Costs. Advertising costs are expensed as incurred. We do not have any direct-response advertising. Advertising costs, which include trade shows and conventions, were approximately $3,902, $6,044, and $8,226 for the years ended March 31, 2021, 2020, and 2019, respectively, and were included in selling, general and administrative expenses in the accompanying consolidated statements of net income and comprehensive income.
Earnings per Share	Earnings per Share. We provide a dual presentation of “basic” and “diluted” earnings per share (“EPS”). Shares below are in thousands. Fiscal Year Ended March 31, 2021 2020 2019 Earnings per share — Basic: Net income $ 9,515 $ 7,498 $ 24,494 Weighted-average shares outstanding — Basic 66,739 65,474 64,417 Net income per common share — Basic $ 0.14 $ 0.11 $ 0.38 Earnings per share — Diluted: Net income $ 9,515 $ 7,498 $ 24,494 Weighted-average shares outstanding 66,739 65,474 64,417 Effect of potentially dilutive securities 146 138 183 Weighted-average shares outstanding — Diluted 66,885 65,612 64,600 Net income per common share — Diluted $ 0.14 $ 0.11 $ 0.38 The computation of diluted net income per share does not include 1,949, 1,807 and 1,963 options for the years ended March 31, 2021, 2020, and 2019, respectively, because their inclusion would have an anti-dilutive effect on net income per share.
Share-Based Compensation	Share-Based Compensation. The following table shows total share-based compensation expense included in the consolidated statements of net income and comprehensive income for the fiscal year ended March 31, 2021, 2020, and 2019: Fiscal Year Ended March 31, 2021 2020 2019 Costs and expenses: Cost of revenue $ 1,991 $ 2,051 $ 1,252 Research and development costs 4,036 3,875 2,919 Selling, general and administrative 16,683 13,768 11,931 Total share-based compensation 22,710 19,694 16,102 Income tax benefit (5,415 ) (4,726 ) (3,859 ) Decrease in net income $ 17,295 $ 14,968 $ 12,243
Recent Accounting Standards	Recently Adopted Accounting Pronouncements. Recently adopted accounting pronouncements are discussed below or in the notes, where applicable. In August 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-15, Intangibles–Goodwill and Other–Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework–Changes to the Disclosure Requirements for Fair Value Measurement In January 2017, the FASB issued ASU 2017-04, Intangibles–Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Recent Accounting Standards Not Yet Adopted. Recent accounting pronouncements requiring implementation in current or future periods are discussed below or in the notes, where applicable. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting Reference Rate Reform (Topic 848): Scope Topic 848 amended and restated revolving credit agreement Topic 848 e are currently in the process of evaluating the potential impact of adoption of this updated authoritative guidance on our consolidated financial statements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes e do not expect the adoption of this new standard to have a material impact on our consolidated financial statements We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.
Revenue Recognition and Performance Obligations	We generate revenue from sales of licensing rights and subscriptions to our software solutions, hardware and third-party software products, support and maintenance, managed services, EDI, and other non-recurring services, including implementation, training, and consulting services. Our contracts with customers may include multiple performance obligations that consist of various combinations of our software solutions and related services, which are generally capable of being distinct and accounted for as separate performance obligations. The total transaction price is allocated to each performance obligation within a contract based on estimated standalone selling prices. We generally determine standalone selling prices based on the prices charged to customers, except for certain software licenses that are based on the residual approach because their standalone selling prices are highly variable and certain maintenance customers that are based on substantive renewal rates. In instances where standalone selling price is not sufficiently observable, such as RCM services and software licenses included in our RCM arrangements, we estimate standalone selling price utilizing an expected cost plus a margin approach. When standalone selling prices are not observable, significant judgment is required in estimating the standalone selling price for each performance obligation. Revenue is recognized when control of the promised goods or services is transferred to our customers in an amount that reflects the consideration that we expect to be entitled to in exchange for those goods or services. We exclude sales tax from the measurement of the transaction price and record revenue net of taxes collected from customers and subsequently remitted to governmental authorities.
Revenue Recognition	Recurring revenues consists of subscription services, support and maintenance, managed services, and EDI and data services. Software, hardware, and other non-recurring revenues consists of revenue from sales of software license and hardware and certain non-recurring services, such as implementation, training, and consulting performed for clients who use our products. We generally recognize revenue for our most significant performance obligations as follows: Subscription services. Performance obligations involving subscription services, which include annual libraries, are satisfied over time as the customer simultaneously receives and consumes the benefits of the services throughout the contract period. Our subscription services primarily include our software-as-a-service (“SaaS”) based offerings, such as our electronic health records and practice management, mobile, patient portal, and population health management solutions. Our SaaS-based offerings may include multiple goods and services, such as providing access to our technology-based solutions together with our managed cloud hosting services. These offerings are concurrently delivered with the same pattern of transfer to our customers and are accounted for as a single performance obligation because the technology-based solutions and other goods and services included within our overall SaaS-based offerings are each individually not capable of being distinct as the customer receives benefits based on the combined offering. Our annual libraries primarily consist of providing stand-ready access to certain content, knowledgebase, databases, and SaaS-based educational tools, which are frequently updated to meet the most current standards and requirements, to be utilized in conjunction with our core solutions. We recognize revenue related to these subscription services, including annual libraries, ratably over the respective noncancelable contract term. Support and maintenance. Performance obligations involving support and maintenance are satisfied over time as the customer simultaneously receives and consumes the benefits of the maintenance services provided. Our support and maintenance services may consist of separate performance obligations, such as unspecified upgrades or enhancements and technical support, which are considered stand-ready in nature and can be offered at various points during the service period. Since the efforts associated with the combined support and maintenance services are rendered concurrently and provided evenly throughout the service period, we consider the series of support and maintenance services to be a single performance obligation. Therefore, we recognize revenue related to these services ratably over the respective noncancelable contract term. Managed services. Managed services consist primarily of RCM and related services, but also includes our hosting services, which we refer to as managed cloud services, transcription services, patient pay services, and certain other recurring services. Performance obligations associated with RCM services are satisfied over time as the customer simultaneously receives and consumes the benefits of the services executed throughout the contract period. The majority of service fees under our RCM arrangements are variable consideration contingent upon collections by our clients. We estimate the variable consideration which we expect to be entitled to over the noncancelable contract term associated with our RCM service arrangements. The estimate of variable consideration included in the transaction price typically involves estimating the amounts we will ultimately collect on behalf of our clients and the relative fee we charge that is generally calculated as a percentage of those collections. Inputs to these estimates include, but are not limited to, historical service fees and collections amounts, timing of historical collections relative to the timing of when claims are submitted by our clients to their respective payers, macroeconomic trends, and anticipated changes in the number of providers. Significant judgement is required when estimating the total transaction price based on the variable consideration. We may apply certain constraints when appropriate whereby we include in the transaction price estimated variable consideration only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Such estimates are assessed at the contract level. RCM and related services may not be rendered evenly over the contract period as the timing of services are based on customer collections, which may vary throughout the service period. We recognize revenue for RCM based on the amount of collections received throughout the contract term as it most closely depicts our efforts to transfer our service obligations to the customer. Our managed cloud services represent a single performance obligation to provide cloud hosting services to our customers and related revenue is recognized ratably over the respective noncancelable contract term. Performance obligations related to the transcription services , patient pay services, and other recurring services are satisfied as the corresponding services are provided and revenue is recognized as such services are rendered. Electronic data interchange and data services. Performance obligations related to EDI and other transaction processing services are satisfied at the point in time the services are rendered. The transfer of control occurs when the transaction processing services are delivered and the customer receives the benefits from the services provided. Software license and hardware. Software license and hardware are considered point-in-time performance obligations as control is transferred to customers upon the delivery of the software license and hardware. Our software licenses are considered functional licenses, and revenue recognition generally occurs on the date of contract execution as the customer is provided with immediate access to the license. We generally determine the amount of consideration allocated to the software license performance obligation using the residual approach, except for certain RCM arrangements where the amount allocated to the software license performance obligation is determined based on estimated relative standalone selling prices. For hardware, we recognize revenue upon transfer of such hardware or devices to the customer. Other non-recurring services. Performance obligations related to other non-recurring services, including implementation, training, and consulting services, are generally satisfied as the corresponding services are provided. Once the services have been provided to the customer, the transfer of control has occurred. Therefore, we recognize revenue as such services are rendered.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Weighted Average Shares Outstanding for Basic and Diluted Net Income Per Share	We provide a dual presentation of “basic” and “diluted” earnings per share (“EPS”). Shares below are in thousands. Fiscal Year Ended March 31, 2021 2020 2019 Earnings per share — Basic: Net income $ 9,515 $ 7,498 $ 24,494 Weighted-average shares outstanding — Basic 66,739 65,474 64,417 Net income per common share — Basic $ 0.14 $ 0.11 $ 0.38 Earnings per share — Diluted: Net income $ 9,515 $ 7,498 $ 24,494 Weighted-average shares outstanding 66,739 65,474 64,417 Effect of potentially dilutive securities 146 138 183 Weighted-average shares outstanding — Diluted 66,885 65,612 64,600 Net income per common share — Diluted $ 0.14 $ 0.11 $ 0.38
Schedule of Stock-Based Compensation Expense	The following table shows total share-based compensation expense included in the consolidated statements of net income and comprehensive income for the fiscal year ended March 31, 2021, 2020, and 2019: Fiscal Year Ended March 31, 2021 2020 2019 Costs and expenses: Cost of revenue $ 1,991 $ 2,051 $ 1,252 Research and development costs 4,036 3,875 2,919 Selling, general and administrative 16,683 13,768 11,931 Total share-based compensation 22,710 19,694 16,102 Income tax benefit (5,415 ) (4,726 ) (3,859 ) Decrease in net income $ 17,295 $ 14,968 $ 12,243

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Schedule of Revenues Disaggregated by Major Revenue Categories and by Occurrence	The following table presents our revenues disaggregated by our major revenue categories and by occurrence: Fiscal Year Ended March 31, 2021 2020 2019 Recurring revenues: Subscription services $ 148,403 $ 127,602 $ 117,502 Support and maintenance 152,956 158,619 160,798 Managed services 103,138 104,549 98,203 Electronic data interchange and data services 98,322 98,543 97,418 Total recurring revenues 502,819 489,313 473,921 Software, hardware, and other non-recurring revenues: Software license and hardware 28,825 27,270 35,122 Other non-recurring services 25,177 23,656 20,130 Total software, hardware and other non-recurring revenues 54,002 50,926 55,252 Total revenues $ 556,821 $ 540,239 $ 529,173

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Summary of Accounts Receivable	Accounts receivable includes invoiced amounts where the right to receive payment is unconditional and only subject to the passage of time. Allowance for doubtful accounts are reported as a component of accounts receivable as summarized below: March 31, 2021 March 31, 2020 Accounts receivable, gross $ 81,746 $ 83,555 Allowance for doubtful accounts (4,205 ) (3,549 ) Accounts receivable, net $ 77,541 $ 80,006
Summary of Changes in Allowance for Doubtful Accounts	The following table represents the changes in the allowance for doubtful accounts, as of and for the twelve months ended March 31, 2021 and 2020: Balance as of March 31, 2019 $ (6,054 ) Additions charged to costs and expenses (3,367 ) Deductions 5,872 Balance as of March 31, 2020 (3,549 ) Additions charged to costs and expenses (2,834 ) Deductions 2,178 Balance as of March 31, 2021 $ (4,205 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value of Assets and Liabilities on a Recurring Basis	The following tables set forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis at March 31, 2021 and March 31, 2020: Balance At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Unobservable Inputs March 31, 2021 (Level 1) (Level 2) (Level 3) ASSETS Cash and cash equivalents (1) $ 73,295 $ 73,295 $ — $ — Restricted cash and cash equivalents 5,280 5,280 — — $ 78,575 $ 78,575 $ — $ — LIABILITIES Contingent consideration related to acquisitions $ 533 $ — $ 533 $ — $ 533 $ — $ 533 $ — Balance At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Unobservable Inputs March 31, 2020 (Level 1) (Level 2) (Level 3) ASSETS Cash and cash equivalents (1) $ 138,012 $ 138,012 $ — $ — Restricted cash and cash equivalents 2,307 2,307 — — $ 140,319 $ 140,319 $ — $ — LIABILITIES Contingent consideration related to acquisitions $ 1,900 $ — $ — $ 1,900 $ 1,900 $ — $ — $ 1,900 (1) Cash equivalents consist primarily of money market funds.
Financial Assets and Liabilities Measured At Fair Value Using Significant Unobservable Inputs (Level 3)	The following table presents activity in our financial assets and liabilities measured at fair value using significant unobservable inputs (Level 3), as of and for the year ended March 31, 2021: Balance at March 31, 2019 $ 1,000 Acquisition 1,850 Fair value adjustments (950 ) Balance at March 31, 2020 1,900 Fair value adjustments (1,367 ) Transfer of Topaz contingent consideration to Level 2 (533 ) Balance at March 31, 2021 $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Summary of Components of Operating Lease Costs	Components of operating lease costs are summarized as follows: Fiscal Year Ended March 31, 2021 2020 Operating lease costs $ 8,235 $ 9,558 Short-term lease costs 25 102 Variable lease costs 1,444 827 Less: Sublease income (514 ) (178 ) Total operating lease costs $ 9,190 $ 10,309
Supplemental Cash Flow Information Related to Operating Leases	Supplemental cash flow information related to operating leases is summarized as follows: Fiscal Year Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of operating lease liabilities $ 18,651 $ 11,527 Operating lease assets obtained in exchange for operating lease liabilities 3,107 8,494
Summary of Future Minimum Aggregate Lease Payments Operating Leases	Future minimum aggregate lease payments under operating leases as of March 31, 2021 are summarized as follows: For the year ended March 31, 2022 $ 13,725 2023 8,220 2024 6,272 2025 3,790 2026 1,257 Total future lease payments 33,264 Less interest (2,076 ) Total lease liabilities $ 31,188

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Summary of Purchase Price Allocation	The final purchase price for the acquisitions of Topaz, Medfusion, and OTTO are summarized as follows: Topaz Medfusion OTTO Purchase Price Purchase Price Purchase Price Initial purchase price $ 8,000 $ 43,000 $ 22,000 Settlement of pre-existing net liabilities 1,671 24 19 Fair value of contingent consideration 1,850 — — Working capital adjustment (344 ) (148 ) (59 ) Total purchase price $ 11,177 $ 42,876 $ 21,960 Fair value of the net tangible assets acquired and liabilities assumed: Acquired cash and cash equivalents $ 353 $ 204 $ 102 Accounts receivable 1,528 986 51 Prepaid expense and other assets 139 387 79 Equipment and improvements 194 434 — Operating lease assets 534 — — Accounts payable (224 ) (1,360 ) (2 ) Accrued compensation and related benefits (155 ) (270 ) (123 ) Contract liabilities (370 ) (529 ) (11 ) Deferred income tax liability — (953 ) — Operating lease liabilities (240 ) — — Operating lease liabilities, net of current (360 ) — — Other liabilities (102 ) (443 ) (26 ) Total net tangible assets acquired and liabilities assumed 1,297 (1,544 ) 70 Fair value of identifiable intangible assets acquired: Goodwill 5,380 23,570 19,490 Software technology 4,500 13,800 2,400 Customer relationships — 6,800 — Trade names — 250 — Total identifiable intangible assets acquired 9,880 44,420 21,890 Total purchase price $ 11,177 $ 42,876 $ 21,960

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, Other than Capitalized Software Development Costs	Our definite-lived intangible assets, other than capitalized software development costs, are summarized as follows: March 31, 2021 Customer Relationships Trade Names Software Technology Total Gross carrying amount $ 39,200 $ 250 $ 91,500 $ 130,950 Accumulated amortization (26,349 ) (67 ) (67,834 ) (94,250 ) Net intangible assets $ 12,851 $ 183 $ 23,666 $ 36,700 March 31, 2020 Customer Relationships Trade Names Software Technology Total Gross carrying amount $ 39,200 $ 250 $ 113,700 $ 153,150 Accumulated amortization (21,951 ) (17 ) (73,373 ) (95,341 ) Net intangible assets $ 17,249 $ 233 $ 40,327 $ 57,809
Estimated Amortization of Intangible Assets with Determinable Lives	The following table summarizes the remaining estimated amortization of definite-lived intangible assets as of March 31, 2021: Estimated Remaining Amortization Expense Operating Expense Cost of Revenue Total For the year ended March 31, 2022 $ 3,525 $ 8,873 $ 12,398 2023 2,820 5,154 7,974 2024 2,279 3,573 5,852 2025 1,846 3,573 5,419 2026 1,377 2,251 3,628 2027 and beyond 1,187 242 1,429 Total $ 13,034 $ 23,666 $ 36,700

Capitalized Software Costs (Tab

Capitalized Software Costs (Tables)	12 Months Ended
	Mar. 31, 2021
Research And Development [Abstract]
Capitalized Software Development Costs	Our capitalized software costs are summarized as follows: March 31, 2021 March 31, 2020 Gross carrying amount $ 96,908 $ 75,212 Accumulated amortization (55,434 ) (38,208 ) Net capitalized software costs $ 41,474 $ 37,004
Estimated Amortization of Capitalized Software Costs	The following table presents the remaining estimated amortization of capitalized software costs as of March 31, 2021. The estimated amortization is comprised of (i) amortization of released products and (ii) the expected amortization for products that are not yet available for sale based on their estimated economic lives and projected general release dates. For the year ended March 31, 2022 $ 24,200 2023 11,800 2024 5,400 2025 74 Total $ 41,474

Composition of Certain Financ_2

Composition of Certain Financial Statement Captions (Tables)	12 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Cash, Cash Equivalents, and Restricted Cash	Cash, cash equivalents, and restricted cash are summarized as follows: March 31, 2021 March 31, 2020 Cash and cash equivalents $ 73,295 $ 138,012 Restricted cash and cash equivalents 5,280 2,307 Cash, cash equivalents, and restricted cash $ 78,575 $ 140,319
Summary of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets are summarized as follows: March 31, 2021 March 31, 2020 Prepaid expenses $ 20,679 $ 18,025 Capitalized commissions costs 9,399 7,053 Other current assets 1,204 1,227 Prepaid expenses and other current assets $ 31,282 $ 26,305
Summary of Equipment and Improvements	Equipment and improvements are summarized as follows: March 31, 2021 March 31, 2020 Computer equipment and software $ 35,244 $ 34,756 Internal-use software 18,174 17,796 Furniture and fixtures 11,555 12,477 Leasehold improvements 14,418 13,681 Equipment and improvements, gross 79,391 78,710 Accumulated depreciation and amortization (64,852 ) (58,874 ) Equipment and improvements, net $ 14,539 $ 19,836
Summary of Other Assets	Other assets are summarized as follows: March 31, 2021 March 31, 2020 Capitalized commission costs $ 19,104 $ 17,537 Deposits 5,505 6,074 Debt issuance costs 2,521 2,124 Other noncurrent assets 9,891 7,921 Other assets $ 37,021 $ 33,656
Summary of Accrued Compensation and Related Benefits	Accrued compensation and related benefits are summarized as follows: March 31, 2021 March 31, 2020 Accrued bonus $ 29,382 $ 10,396 Accrued vacation 12,038 10,469 Accrued commissions 4,628 2,087 Deferred payroll taxes 3,817 — Accrued payroll and other 509 840 Accrued compensation and related benefits $ 50,374 $ 23,792
Summary of Other Current and Noncurrent Liabilities	Other current and noncurrent liabilities are summarized as follows: March 31, 2021 March 31, 2020 Sales returns reserves and other customer liabilities $ 9,449 $ 6,395 Accrued legal expense 6,302 2,119 Accrued hosting costs 6,158 4,652 Care services liabilities 5,280 2,307 Accrued employee benefits and withholdings 4,649 3,002 Customer credit balances and deposits 4,638 4,260 Accrued royalties 3,125 3,113 Accrued consulting and outside services 3,002 2,520 Accrued outsourcing costs 2,266 2,378 Accrued EDI expense 2,020 3,511 Accrued self insurance expense 1,737 2,054 Accrued taxes payable 586 1,222 Contingent consideration related to acquisitions 533 — Other accrued expenses 2,954 3,819 Other current liabilities $ 52,699 $ 41,352 Deferred payroll taxes $ 3,817 $ — Uncertain tax positions 3,175 1,203 Contingent consideration related to acquisitions — 1,900 Other liabilities 144 178 Other noncurrent liabilities $ 7,136 $ 3,281

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Summary of Provision for (Benefit of) Income Taxes	The provision for (benefit of) income taxes consists of the following components: Fiscal Year Ended March 31, 2021 2020 2019 Current: Federal taxes $ 6,562 $ 408 $ 1,159 State taxes 1,226 858 (238 ) Foreign taxes 826 874 744 Total current taxes 8,614 2,140 1,665 Deferred: Federal taxes $ (6,053 ) $ (3,578 ) $ 3,752 State taxes (2,068 ) (1,682 ) (428 ) Foreign taxes (733 ) (119 ) (195 ) Total deferred taxes (8,854 ) (5,379 ) 3,129 Provision for (benefit of) income taxes $ (240 ) $ (3,239 ) $ 4,794
Summary of Provision for (Benefit of) Income Taxes Differs from the Amount Computed at Federal Statutory Rate	The provision for (benefit of) income taxes differs from the amount computed at the federal statutory rate as follows: Fiscal Year Ended March 31, 2021 2020 2019 Tax expense at United States federal statutory rate (1) $ 1,948 $ 895 $ 6,150 Items affecting federal income tax rate: Research and development tax credits (3,449 ) (4,705 ) (4,647 ) Impact of foreign operations (1,203 ) (683 ) (304 ) Impact of deferred adjustments (251 ) 159 132 Impact of audit settlements (56 ) (61 ) 967 Return to provision true-ups (15 ) (1,868 ) (149 ) Impact of amended returns (9 ) 67 391 Acquisition expenses — 229 (2 ) Foreign transition tax - Tax Reform — — 210 Revaluation of deferred tax balances - Tax Reform — — 231 Impact of uncertain tax positions 278 1,062 375 Non-deductible expenses 517 903 140 Impact of valuation allowance 563 (49 ) (33 ) State income taxes 572 687 1,502 Compensation 865 125 (169 ) Provision for (benefit of) income taxes $ (240 ) $ (3,239 ) $ 4,794 (1 ) 21.0%
Summary of Net Deferred Tax Assets and Liabilities	The net deferred tax assets and liabilities in the accompanying consolidated balance sheets consist of the following: March 31, 2021 March 31, 2020 Deferred tax assets: Compensation and benefits $ 19,541 $ 11,966 Deferred revenue 8,325 10,546 Research and development credit 7,706 9,643 Net operating losses 7,652 8,812 Operating lease liabilities 6,204 11,430 Foreign deferred taxes 2,306 1,574 Allowance for doubtful accounts 1,819 1,819 Accrued legal settlement 905 — Total deferred tax assets 54,458 55,790 Deferred tax liabilities: Intangibles assets $ (9,451 ) $ (12,477 ) Prepaid expense (9,396 ) (7,842 ) Capitalized software (4,659 ) (9,931 ) Operating right-of-use assets (3,003 ) (6,667 ) Accelerated depreciation (1,339 ) (1,405 ) Other (611 ) (145 ) Accounts receivable (510 ) (1,251 ) Total deferred tax liabilities (28,969 ) (39,718 ) Valuation allowance (6,015 ) (5,452 ) Deferred tax assets, net $ 19,474 $ 10,620
Summary of Reconciliation in Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits, which is recorded within other noncurrent liabilities in our consolidated balance sheet, is as follows: Balance as of March 31, 2019 $ 2,894 Additions for prior year tax positions 1,372 Additions for current year tax positions 781 Reductions for prior year tax positions (855 ) Balance as of March 31, 2020 4,192 Additions for prior year tax positions 220 Additions for current year tax positions 635 Reductions for prior year tax positions (621 ) Balance as of March 31, 2021 $ 4,426

Share Based Awards (Tables)

Share Based Awards (Tables)	12 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	The following table summarizes the stock option transactions during the years ended March 31, 2021, 2020, and 2019: Weighted- Weighted- Average Average Aggregate Exercise Remaining Intrinsic Number of Price Contractual Value Shares per Share Life (years) (in thousands) Outstanding, March 31, 2018 3,670,170 $ 15.51 6.2 $ 766 Granted 326,130 16.40 6.8 Exercised (375,645 ) 15.49 4.7 1,589 Forfeited/Canceled (451,730 ) 18.00 4.9 Expired (2,400 ) 28.15 Outstanding, March 31, 2019 3,166,525 $ 15.36 5.5 $ 7,040 Exercised (55,325 ) 15.87 4.3 138 Forfeited/Canceled (75,450 ) 23.38 1.5 Expired (34,400 ) 43.04 Outstanding, March 31, 2020 3,001,350 $ 14.83 4.7 $ — Exercised (116,916 ) 16.21 3.3 303 Forfeited/Canceled (47,350 ) 18.58 3.7 Expired (46,000 ) 29.17 Outstanding, March 31, 2021 2,791,084 $ 14.47 3.7 $ 10,303 Vested and expected to vest, March 31, 2021 2,715,933 $ 14.45 3.7 $ 10,075 Exercisable, March 31, 2021 2,331,745 $ 14.33 3.6 $ 8,910
Summary of Stock Options Granted	There were no stock options granted during the years ended March 31, 2021 and 2020. During the year ended March 31, 2019, we granted total stock options of 326,130, to purchase shares of common stock under the Amended 2015 Plan at an exercise price equal to the market price of our common stock on the date of grant, as summarized below. Option Grant Date Number of Shares Exercise Price Vesting Terms (1) Expiration May 30, 2018 241,130 $ 16.83 Four Years June 1, 2026 August 3, 2018 60,000 $ 21.27 Four Years August 3, 2026 November 2, 2018 25,000 $ 15.09 Four Years November 2, 2026 Fiscal year 2019 grants 326,130 (1) Unless otherwise indicated, options vest in equal annual installments on each grant anniversary date commencing one year following the date of grant
Schedule of Assumptions Used in Black-Scholes Model to Estimate Fair Value of Stock Awards	We utilized the Black-Scholes valuation model for estimating the fair value of share-based compensation with the following assumptions: Year Ended March 31, 2019 Expected term 6.1 - 6.3 years Expected volatility 34.6% - 36.8% Expected dividends 0.0% Risk-free rate 2.8% - 3.1%
Schedule of Employee Stock Options and Performance Based Awards by Non-vested Stock Options	Non-vested stock option award activity during the years ended March 31, 2021, 2020, and 2019 is summarized as follows: Weighted- Average Grant-Date Number of Fair Value Shares per Share Outstanding, March 31, 2018 2,657,005 $ 5.18 Granted 326,130 7.18 Vested (778,900 ) 5.12 Forfeited/Canceled (358,380 ) 5.36 Outstanding, March 31, 2019 1,845,855 $ 5.52 Vested (745,033 ) 5.29 Forfeited/Canceled (9,150 ) 6.42 Outstanding, March 31, 2020 1,091,672 $ 5.67 Vested (605,433 ) 5.40 Forfeited/Canceled (26,900 ) 6.80 Outstanding, March 31, 2021 459,339 $ 5.96
Summary of Restricted Stock Awards Activity	Restricted stock awards activity during the years ended March 31, 2021, 2020, and 2019 is summarized as follows: Weighted- Average Grant-Date Number of Fair Value Shares per Share Outstanding, March 31, 2018 1,820,910 $ 14.52 Granted 885,845 18.14 Vested (642,695 ) 14.63 Canceled (348,102 ) 14.79 Outstanding, March 31, 2019 1,715,958 $ 16.29 Granted 1,529,831 16.93 Vested (764,290 ) 16.05 Canceled (168,719 ) 17.06 Outstanding, March 31, 2020 2,312,780 $ 16.74 Granted 1,222,863 12.04 Vested (1,053,792 ) 16.22 Canceled (218,282 ) 15.30 Outstanding, March 31, 2021 2,263,569 $ 14.58

Organization of Business - Addi

Organization of Business - Additional Information (Details)	12 Months Ended
	Mar. 31, 2021StateProvider
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of states serving to clients | State	50
Number of providers using healthcare solutions to deliver care | Provider	100,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2021USD ($)segmentshares	Mar. 31, 2020USD ($)segmentshares	Mar. 31, 2019USD ($)shares
Accounting Policies [Line Items]
Number of operating segments | segment	1	1
Maturity of time deposits	90 days
Cash, FDIC insured amount	$ 250
Cash and cash equivalents	73,295	$ 138,012
Cash, uninsured amount	86,317
Depreciation	7,997	8,172	$ 10,298
Advertising costs	$ 3,902	$ 6,044	$ 8,226
Employee Stock Options
Accounting Policies [Line Items]
Options excluded from the computation of diluted net income per share | shares	1,949	1,807	1,963
Minimum
Accounting Policies [Line Items]
Amortization period of intangible assets	5 years
Maximum
Accounting Policies [Line Items]
Amortization period of intangible assets	10 years
Computer Equipment and Software | Minimum
Accounting Policies [Line Items]
Useful life	3 years
Computer Equipment and Software | Maximum
Accounting Policies [Line Items]
Useful life	5 years
Furniture and Fixtures | Minimum
Accounting Policies [Line Items]
Useful life	3 years
Furniture and Fixtures | Maximum
Accounting Policies [Line Items]
Useful life	7 years
Leasehold Improvements
Accounting Policies [Line Items]
Useful life, description	lesser of lease term or estimated useful life of asset
Capitalized Software Costs
Accounting Policies [Line Items]
Useful life	3 years
Accounting Standards Update 2014-09
Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Apr. 1, 2018
Accounting Standards Update 2016-02
Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Apr. 1, 2019
Accounting Standards Update 2018-15
Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Apr. 1, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
Accounting Standards Update 2018-13
Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Apr. 1, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
Accounting Standards Update 2017-04
Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Apr. 1, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true
Accounting Standards Update 2016-13
Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Apr. 1, 2020
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	true

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Weighted Average Shares Outstanding for Basic and Diluted Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Earnings per share — Basic:
Net income	$ 9,515	$ 7,498	$ 24,494
Weighted-average shares outstanding — Basic	66,739	65,474	64,417
Net income per common share — Basic	$ 0.14	$ 0.11	$ 0.38
Earnings per share — Diluted:
Net income	$ 9,515	$ 7,498	$ 24,494
Weighted-average shares outstanding — Basic	66,739	65,474	64,417
Effect of potentially dilutive securities	146	138	183
Weighted-average shares outstanding — Diluted	66,885	65,612	64,600
Net income per common share — Diluted	$ 0.14	$ 0.11	$ 0.38

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Costs and expenses:
Total share-based compensation	$ 22,710	$ 19,694	$ 16,102
Income tax benefit	(5,415)	(4,726)	(3,859)
Decrease in net income	17,295	14,968	12,243
Cost of Revenue
Costs and expenses:
Total share-based compensation	1,991	2,051	1,252
Research and Development Costs
Costs and expenses:
Total share-based compensation	4,036	3,875	2,919
Selling, General and Administrative
Costs and expenses:
Total share-based compensation	$ 16,683	$ 13,768	$ 11,931

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Schedule of Revenues Disaggregated by Major Revenue Categories and by Occurrence (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disaggregation Of Revenue [Line Items]
Total revenues	$ 556,821	$ 540,239	$ 529,173
Subscription Services
Disaggregation Of Revenue [Line Items]
Total revenues	148,403	127,602	117,502
Support And Maintenance
Disaggregation Of Revenue [Line Items]
Total revenues	152,956	158,619	160,798
Managed Services
Disaggregation Of Revenue [Line Items]
Total revenues	103,138	104,549	98,203
Electronic Data Interchange And Data Services
Disaggregation Of Revenue [Line Items]
Total revenues	98,322	98,543	97,418
Recurring Revenue
Disaggregation Of Revenue [Line Items]
Total revenues	502,819	489,313	473,921
Software License and Hardware
Disaggregation Of Revenue [Line Items]
Total revenues	28,825	27,270	35,122
Other Non-recurring Services
Disaggregation Of Revenue [Line Items]
Total revenues	25,177	23,656	20,130
Software Hardware and Other Non-recurring
Disaggregation Of Revenue [Line Items]
Total revenues	$ 54,002	$ 50,926	$ 55,252

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Revenue From Contract With Customer [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 548,800	$ 483,200
Percentage of revenue expected to recognize as services rendered and goods delivered	9.00%	9.00%
Percentage of revenue expected to recognize over next 12 months	53.00%	50.00%
Contract liability balance or invoiced to customers	$ 74,097	$ 70,779
Capitalized commission costs	28,503	24,590
Commission expenses	11,236	8,006	$ 6,292
Prepaid Expenses And Other Current Assets
Revenue From Contract With Customer [Line Items]
Capitalized commission costs	9,399	7,053
Other Noncurrent Assets
Revenue From Contract With Customer [Line Items]
Capitalized commission costs	$ 19,104	$ 17,537
Minimum
Revenue From Contract With Customer [Line Items]
Capitalized contract cost, amortization period	1 year
Maximum
Revenue From Contract With Customer [Line Items]
Capitalized contract cost, amortization period	5 years

Accounts Receivable - Summary o

Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Receivables [Abstract]
Accounts receivable, gross	$ 81,746	$ 83,555
Allowance for doubtful accounts	(4,205)	(3,549)	$ (6,054)
Accounts receivable, net	$ 77,541	$ 80,006

Accounts Receivable - Summary_2

Accounts Receivable - Summary of Changes in Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Receivables [Abstract]
Balance	$ (3,549)	$ (6,054)
Additions charged to costs and expenses	(2,834)	(3,367)	$ (5,644)
Deductions	2,178	5,872
Balance	$ (4,205)	$ (3,549)	$ (6,054)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities on a Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands		Mar. 31, 2021	Mar. 31, 2020
Carrying Value
ASSETS
Cash and cash equivalents	[1]	$ 73,295	$ 138,012
Restricted cash and cash equivalents		5,280	2,307
Total		78,575	140,319
LIABILITIES
Contingent consideration related to acquisitions		533	1,900
Total		533	1,900
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value
ASSETS
Cash and cash equivalents	[1]	73,295	138,012
Restricted cash and cash equivalents		5,280	2,307
Total		78,575	140,319
LIABILITIES
Contingent consideration related to acquisitions		0	0
Total		0	0
Significant Other Observable Inputs (Level 2) | Fair Value
ASSETS
Cash and cash equivalents	[1]	0	0
Restricted cash and cash equivalents		0	0
Total		0	0
LIABILITIES
Contingent consideration related to acquisitions		533	0
Total		533	0
Unobservable Inputs (Level 3) | Fair Value
ASSETS
Cash and cash equivalents	[1]	0	0
Restricted cash and cash equivalents		0	0
Total		0	0
LIABILITIES
Contingent consideration related to acquisitions		0	1,900
Total		$ 0	$ 1,900
[1]	Cash equivalents consist primarily of money market funds.

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Measured At Fair Value Using Significant Unobservable Inputs (Level 3) (Details ) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Company's assets measured at fair value using significant unobservable inputs (Level 3)
Balance	$ 1,900	$ 1,000
Acquisition		1,850
Fair value adjustments	(1,367)	(950)	$ 1,000
Balance		$ 1,900	$ 1,000
Topaz Information Systems, LLC | Level 2
Company's assets measured at fair value using significant unobservable inputs (Level 3)
Fair value adjustments	(1,367)
Transfer of Topaz contingent consideration to Level 2	$ (533)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Business Acquisition [Line Items]
Net benefit from fair value adjustments	$ 1,367,000	$ 950,000	$ (1,000,000)
Topaz Information Systems, LLC
Business Acquisition [Line Items]
Contingent consideration related to acquisitions	533,000	1,900,000
Expected earnout payments		0
Fair value of contingent consideration adjustment to accretion of present value discount		50,000
Topaz Information Systems, LLC | Level 2
Business Acquisition [Line Items]
Contingent consideration related to acquisitions	533,000
Net benefit from fair value adjustments	$ 1,367,000
Inforth Technologies L L C
Business Acquisition [Line Items]
Contingent consideration related to acquisitions			$ 1,000,000
Net benefit from fair value adjustments		$ 950,000

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Lessee Lease Description [Line Items]
Total operating lease costs	$ 9,190	$ 10,309	$ 8,174
Operating lease, weighted average remaining lease term	3 years 1 month 6 days
Operating lease, weighted average discount rate, percent	3.50%
Lease Right of Use Assets and Property Plant and Equipment
Lessee Lease Description [Line Items]
Other asset impairment charges	$ 5,539	$ 9,373
Minimum
Lessee Lease Description [Line Items]
Lease expiration year	2021
Maximum
Lessee Lease Description [Line Items]
Lease expiration year	2026

Leases - Summary of Components

Leases - Summary of Components of Operating Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease costs	$ 8,235	$ 9,558
Short-term lease costs	25	102
Variable lease costs	1,444	827
Less: Sublease income	(514)	(178)
Total operating lease costs	$ 9,190	$ 10,309	$ 8,174

Leases - Supplemental Cash Flow

Leases - Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 18,651	$ 11,527
Operating lease assets obtained in exchange for operating lease liabilities	$ 3,107	$ 8,494

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Aggregate Lease Payments Operating Leases (Details) $ in Thousands	Mar. 31, 2021USD ($)
Leases [Abstract]
2022	$ 13,725
2023	8,220
2024	6,272
2025	3,790
2026	1,257
Total future lease payments	33,264
Less interest	(2,076)
Total lease liabilities	$ 31,188

Business Combinations - Additio

Business Combinations - Additional Information (Details) - USD ($) $ in Thousands	Dec. 17, 2019	Dec. 06, 2019	Oct. 04, 2019	Mar. 31, 2021
Topaz
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition				Oct. 4, 2019
Business acquisition, date of acquisition agreement				Oct. 4, 2019
Business combination, additional cash in form of earnout			$ 2,000
Contingent consideration related to acquisitions			1,850	$ 533
Settlement of pre-existing liabilities related to pre-acquisition amounts			$ 1,671
Topaz | Computer Software, Intangible Asset
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life			6 years
Medfusion
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition				Dec. 6, 2019
Business acquisition, date of acquisition agreement				Nov. 12, 2019
Measurement period adjustment to goodwill				$ 47
Settlement of pre-existing liabilities related to pre-acquisition amounts		$ 24
Acquired finite-lived intangible assets, weighted average useful life		7 years 3 months 18 days
Medfusion | Computer Software, Intangible Asset
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life		6 years
Medfusion | Customer Relationships
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life		10 years
Medfusion | Trade Names
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life		5 years
OTTO
Business Acquisition [Line Items]
Business acquisition, effective date of acquisition				Dec. 17, 2019
Business acquisition, date of acquisition agreement				Dec. 11, 2019
Settlement of pre-existing liabilities related to pre-acquisition amounts	$ 19
OTTO | Computer Software, Intangible Asset
Business Acquisition [Line Items]
Finite-lived intangible asset, useful life	7 years

Business Combinations - Summary

Business Combinations - Summary of Purchase Price Allocation (Details) - USD ($) $ in Thousands	Dec. 17, 2019	Dec. 06, 2019	Oct. 04, 2019	Mar. 31, 2021	Mar. 31, 2020
Fair value of identifiable intangible assets acquired:
Goodwill				$ 267,212	$ 267,165
Topaz
Business Acquisition [Line Items]
Initial purchase price			$ 8,000
Settlement of pre-existing net liabilities			1,671
Fair value of contingent consideration			1,850	$ 533
Working capital adjustment			(344)
Total purchase price			11,177
Fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents			353
Accounts receivable			1,528
Prepaid expense and other assets			139
Equipment and improvements			194
Operating lease assets			534
Accounts payable			(224)
Accrued compensation and related benefits			(155)
Contract liabilities			(370)
Operating lease liabilities			(240)
Operating lease liabilities, net of current			(360)
Other liabilities			(102)
Total net tangible assets acquired and liabilities assumed			1,297
Fair value of identifiable intangible assets acquired:
Goodwill			5,380
Total identifiable intangible assets acquired			9,880
Total purchase price			11,177
Medfusion
Business Acquisition [Line Items]
Initial purchase price		$ 43,000
Settlement of pre-existing net liabilities		24
Working capital adjustment		(148)
Total purchase price		42,876
Fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents		204
Accounts receivable		986
Prepaid expense and other assets		387
Equipment and improvements		434
Accounts payable		(1,360)
Accrued compensation and related benefits		(270)
Contract liabilities		(529)
Deferred income tax liability		(953)
Other liabilities		(443)
Total net tangible assets acquired and liabilities assumed		(1,544)
Fair value of identifiable intangible assets acquired:
Goodwill		23,570
Total identifiable intangible assets acquired		44,420
Total purchase price		42,876
OTTO
Business Acquisition [Line Items]
Initial purchase price	$ 22,000
Settlement of pre-existing net liabilities	19
Working capital adjustment	(59)
Total purchase price	21,960
Fair value of the net tangible assets acquired and liabilities assumed:
Acquired cash and cash equivalents	102
Accounts receivable	51
Prepaid expense and other assets	79
Accounts payable	(2)
Accrued compensation and related benefits	(123)
Contract liabilities	(11)
Other liabilities	(26)
Total net tangible assets acquired and liabilities assumed	70
Fair value of identifiable intangible assets acquired:
Goodwill	19,490
Total identifiable intangible assets acquired	21,890
Total purchase price	21,960
Computer Software, Intangible Asset | Topaz
Fair value of identifiable intangible assets acquired:
Total identifiable intangible assets acquired			$ 4,500
Computer Software, Intangible Asset | Medfusion
Fair value of identifiable intangible assets acquired:
Total identifiable intangible assets acquired		13,800
Computer Software, Intangible Asset | OTTO
Fair value of identifiable intangible assets acquired:
Total identifiable intangible assets acquired	$ 2,400
Customer Relationships | Medfusion
Fair value of identifiable intangible assets acquired:
Total identifiable intangible assets acquired		6,800
Trade Names | Medfusion
Fair value of identifiable intangible assets acquired:
Total identifiable intangible assets acquired		$ 250

Goodwill - Additional Informati

Goodwill - Additional Information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Impairment of goodwill	$ 0	$ 0
Goodwill	$ 267,212,000	$ 267,165,000

Intangible Assets - Intangible

Intangible Assets - Intangible Assets, Other than Capitalized Software Development Costs (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	$ 130,950	$ 153,150
Accumulated amortization	(94,250)	(95,341)
Net intangible assets	36,700	57,809
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	39,200	39,200
Accumulated amortization	(26,349)	(21,951)
Net intangible assets	12,851	17,249
Trade Names
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	250	250
Accumulated amortization	(67)	(17)
Net intangible assets	183	233
Computer Software, Intangible Asset
Finite Lived Intangible Assets [Line Items]
Gross carrying amount	91,500	113,700
Accumulated amortization	(67,834)	(73,373)
Net intangible assets	$ 23,666	$ 40,327

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Finite Lived Intangible Assets [Line Items]
Amortization of other intangibles	$ 21,109	$ 22,536	$ 21,496
Customer Relationships and Trade Names | Operating Expense
Finite Lived Intangible Assets [Line Items]
Amortization of other intangibles	4,449	4,143	4,344
Computer Software, Intangible Asset | Cost of Revenue
Finite Lived Intangible Assets [Line Items]
Amortization of other intangibles	$ 16,660	$ 18,393	$ 17,152

Intangible Assets - Estimated A

Intangible Assets - Estimated Amortization of Intangible Assets with Determinable Lives (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Finite Lived Intangible Assets [Line Items]
2022	$ 12,398
2023	7,974
2024	5,852
2025	5,419
2026	3,628
2027 and beyond	1,429
Net intangible assets	36,700	$ 57,809
Operating Expense
Finite Lived Intangible Assets [Line Items]
2022	3,525
2023	2,820
2024	2,279
2025	1,846
2026	1,377
2027 and beyond	1,187
Net intangible assets	13,034
Cost of Revenue
Finite Lived Intangible Assets [Line Items]
2022	8,873
2023	5,154
2024	3,573
2025	3,573
2026	2,251
2027 and beyond	242
Net intangible assets	$ 23,666

Capitalized Software Costs - Ca

Capitalized Software Costs - Capitalized Software Development Costs (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Research And Development [Abstract]
Gross carrying amount	$ 96,908	$ 75,212
Accumulated amortization	(55,434)	(38,208)
Net capitalized software costs	$ 41,474	$ 37,004

Capitalized Software Costs - Ad

Capitalized Software Costs - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Research And Development [Abstract]
Impairments related to write down of capitalized software costs		$ 3,198
Amortization of capitalized software costs	$ 20,108	$ 17,085	$ 11,338
Retired fully amortized capitalized software costs			$ 13,453

Capitalized Software Costs - Es

Capitalized Software Costs - Estimated Amortization of Capitalized Software Costs (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Finite Lived Intangible Assets [Line Items]
2022	$ 12,398
2023	7,974
2024	5,852
2025	5,419
Net intangible assets	36,700	$ 57,809
Capitalized Software Costs
Finite Lived Intangible Assets [Line Items]
2022	24,200
2023	11,800
2024	5,400
2025	74
Net intangible assets	$ 41,474

Line of Credit - Additional Inf

Line of Credit - Additional Information (Details)	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Mar. 12, 2021USD ($)	Mar. 29, 2018USD ($)
Line Of Credit Facility [Line Items]
Minimum interest coverage ratio	3.50
Line of credit	$ 0	$ 129,000,000
Remaining borrowing capacity	300,000,000	$ 171,000,000
Line of credit facility, interest rate at period end		2.30%
Interest expense	$ 2,541,000	$ 1,274,000	$ 2,055,000
Debt, weighted average interest rate	2.20%	2.40%	3.70%
Additional unamortized debt issuance costs	$ 1,423,000
Debt issuance costs written off	326,000
Amortization of deferred debt issuance costs, including written off	1,026,000	$ 710,000	$ 710,000
Other Assets
Line Of Credit Facility [Line Items]
Debt issuance costs	$ 2,521,000	$ 2,124,000	$ 2,124,000
Maximum | Fiscal Quarter Ending on or Prior to September 30, 2016
Line Of Credit Facility [Line Items]
Leverage ratio	3.75
Revolving Credit Facility
Line Of Credit Facility [Line Items]
Maximum borrowing capacity	$ 150,000,000			$ 300,000,000	$ 300,000,000
Credit agreement maturity date	Mar. 12, 2026
Debt instrument, basis spread on variable rate	1.00%
Revolving Credit Facility | Minimum
Line Of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Line of credit facility, unused capacity, commitment fee percentage	0.25%
Revolving Credit Facility | Maximum
Line Of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	1.75%
Line of credit facility, unused capacity, commitment fee percentage	0.45%
Revolving Credit Facility | Federal Funds Effective Rate
Line Of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Revolving Credit Facility | London Interbank Offered Rate ("LIBOR")
Line Of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	1.00%
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Minimum
Line Of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	1.50%
Revolving Credit Facility | London Interbank Offered Rate (LIBOR) | Maximum
Line Of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	2.75%
Letter of Credit
Line Of Credit Facility [Line Items]
Maximum borrowing capacity				10,000,000
Swing-Line Loans
Line Of Credit Facility [Line Items]
Maximum borrowing capacity				$ 10,000,000

Composition of Certain Financ_3

Composition of Certain Financial Statement Captions - Summary of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 73,295	$ 138,012
Restricted cash and cash equivalents	5,280	2,307
Cash, cash equivalents, and restricted cash	$ 78,575	$ 140,319	$ 34,522	$ 31,218

Composition of Certain Financ_4

Composition of Certain Financial Statement Captions - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Prepaid Expense And Other Assets Current [Abstract]
Prepaid expenses	$ 20,679	$ 18,025
Capitalized commissions costs	9,399	7,053
Other current assets	1,204	1,227
Prepaid expenses and other current assets	$ 31,282	$ 26,305

Composition of Certain Financ_5

Composition of Certain Financial Statement Captions - Summary of Equipment and Improvements (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Property Plant And Equipment [Line Items]
Equipment and improvements, gross	$ 79,391	$ 78,710
Accumulated depreciation and amortization	(64,852)	(58,874)
Equipment and improvements, net	14,539	19,836
Computer Equipment and Software
Property Plant And Equipment [Line Items]
Equipment and improvements, gross	35,244	34,756
Internal-Use Software
Property Plant And Equipment [Line Items]
Equipment and improvements, gross	18,174	17,796
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Equipment and improvements, gross	11,555	12,477
Leasehold Improvements
Property Plant And Equipment [Line Items]
Equipment and improvements, gross	$ 14,418	$ 13,681

Composition of Certain Financ_6

Composition of Certain Financial Statement Captions - Summary of Other Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Other Assets Noncurrent Disclosure [Abstract]
Capitalized commission costs	$ 19,104	$ 17,537
Deposits	5,505	6,074
Debt issuance costs	2,521	2,124
Other noncurrent assets	9,891	7,921
Other assets	$ 37,021	$ 33,656

Composition of Certain Financ_7

Composition of Certain Financial Statement Captions - Summary of Accrued Compensation and Related Benefits (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Employee Related Liabilities Current [Abstract]
Accrued bonus	$ 29,382	$ 10,396
Accrued vacation	12,038	10,469
Accrued commissions	4,628	2,087
Deferred payroll taxes	3,817
Accrued payroll and other	509	840
Accrued compensation and related benefits	$ 50,374	$ 23,792

Composition of Certain Financ_8

Composition of Certain Financial Statement Captions - Summary of Other Current and Noncurrent Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Other Liabilities [Abstract]
Sales returns reserves and other customer liabilities	$ 9,449	$ 6,395
Accrued legal expense	6,302	2,119
Accrued hosting costs	6,158	4,652
Care services liabilities	5,280	2,307
Accrued employee benefits and withholdings	4,649	3,002
Customer credit balances and deposits	4,638	4,260
Accrued royalties	3,125	3,113
Accrued consulting and outside services	3,002	2,520
Accrued outsourcing costs	2,266	2,378
Accrued EDI expense	2,020	3,511
Accrued self insurance expense	1,737	2,054
Accrued taxes payable	586	1,222
Contingent consideration related to acquisitions	533
Other accrued expenses	2,954	3,819
Other current liabilities	52,699	41,352
Deferred payroll taxes	3,817
Uncertain tax positions	3,175	1,203
Contingent consideration related to acquisitions		1,900
Other liabilities	144	178
Other noncurrent liabilities	$ 7,136	$ 3,281

Income Taxes - Summary of Provi

Income Taxes - Summary of Provision for (Benefit of) Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Current:
Federal taxes	$ 6,562	$ 408	$ 1,159
State taxes	1,226	858	(238)
Foreign taxes	826	874	744
Total current taxes	8,614	2,140	1,665
Deferred:
Federal taxes	(6,053)	(3,578)	3,752
State taxes	(2,068)	(1,682)	(428)
Foreign taxes	(733)	(119)	(195)
Total deferred taxes	(8,854)	(5,379)	3,129
Provision for (benefit of) income taxes	$ (240)	$ (3,239)	$ 4,794

Income Taxes - Summary of Pro_2

Income Taxes - Summary of Provision for (Benefit of) Income Taxes Differs from the Amount Computed at Federal Statutory Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Tax expense at United States federal statutory rate	$ 1,948	$ 895	$ 6,150
Research and development tax credits	(3,449)	(4,705)	(4,647)
Impact of foreign operations	(1,203)	(683)	(304)
Impact of deferred adjustments	(251)	159	132
Impact of audit settlements	(56)	(61)	967
Return to provision true-ups	(15)	(1,868)	(149)
Impact of amended returns	(9)	67	391
Acquisition expenses		229	(2)
Foreign transition tax - Tax Reform			210
Revaluation of deferred tax balances - Tax Reform			231
Impact of uncertain tax positions	278	1,062	375
Non-deductible expenses	517	903	140
Impact of valuation allowance	563	(49)	(33)
State income taxes	572	687	1,502
Compensation	865	125	(169)
Provision for (benefit of) income taxes	$ (240)	$ (3,239)	$ 4,794

Income Taxes - Summary of Pro_3

Income Taxes - Summary of Provision for (Benefit of) Income Taxes Differs from the Amount Computed at Federal Statutory Rate (Parenthetical) (Details)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Federal statutory rate	21.00%	21.00%	21.00%

Income Taxes - Summary of Net D

Income Taxes - Summary of Net Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Mar. 31, 2020
Deferred tax assets:
Compensation and benefits	$ 19,541	$ 11,966
Deferred revenue	8,325	10,546
Research and development credit	7,706	9,643
Net operating losses	7,652	8,812
Operating lease liabilities	6,204	11,430
Foreign deferred taxes	2,306	1,574
Allowance for doubtful accounts	1,819	1,819
Accrued legal settlement	905
Total deferred tax assets	54,458	55,790
Deferred tax liabilities:
Intangibles assets	(9,451)	(12,477)
Prepaid expense	(9,396)	(7,842)
Capitalized software	(4,659)	(9,931)
Operating right-of-use assets	(3,003)	(6,667)
Accelerated depreciation	(1,339)	(1,405)
Other	(611)	(145)
Accounts receivable	(510)	(1,251)
Total deferred tax liabilities	(28,969)	(39,718)
Valuation allowance	(6,015)	(5,452)
Deferred tax assets, net	$ 19,474	$ 10,620

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Operating Loss Carryforwards [Line Items]
Foreign withholding related taxes	$ 3,400,000
Unrecognized tax benefits, decrease resulting from prior period tax positions	234,000
Liability for unrecognized tax benefits	4,426,000	$ 4,192,000	$ 2,894,000
Income tax examination, interest accrued	88,000	174,000
Income tax examination, interest income	85,000	35,000
Income tax examination, interest expense			19,000
Income tax examination, penalty accrued	0	0	0
Income tax examination, penalty expense	$ 0	0	$ 0
Period within which the company does not anticipate total unrecognized tax benefits to change	within the next twelve months
Research and Development
Operating Loss Carryforwards [Line Items]
Tax credit carryforward, amount	$ 8,574,000	12,399,000
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	18,748,000	$ 24,216,000
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	3,715,000
Tax effect from change in tax rate	$ 600,000

Income Taxes - Summary of Recon

Income Taxes - Summary of Reconciliation in Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Liability for unrecognized tax benefits	$ 4,192	$ 2,894
Additions for prior year tax positions	220	1,372
Additions for current year tax positions	635	781
Reductions for prior year tax positions	(621)	(855)
Liability for unrecognized tax benefits	$ 4,426	$ 4,192

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, maximum annual contributions per employee, percent	75.00%
Defined contribution plan, maximum annual bonus contributions per employee, percent	100.00%
Deferred compensation	$ 6,620	$ 5,300
Cash surrender value of life insurance	8,126	7,029
401(k) Plan
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, net contributions by employer	4,625	4,658	$ 5,206
Deferred Compensation Plan
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, net contributions by employer	$ 79	$ 74	$ 71

Share Based Awards - Additional

Share Based Awards - Additional Information (Details) - USD ($)

Oct. 26, 2020

Oct. 23, 2018

Dec. 29, 2016

Aug. 11, 2014

Jan. 27, 2020

Mar. 31, 2021

Mar. 31, 2020

Mar. 31, 2019

Aug. 31, 2019

Mar. 31, 2018

Aug. 31, 2017

Aug. 31, 2015

Oct. 31, 2005

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Outstanding stock options

2,791,084

3,001,350

3,166,525

3,670,170

Total share-based compensation

$ 22,710,000

$ 19,694,000

$ 16,102,000

Weighted-average grant date fair value

$ 7.18

Fair value of options vested

$ 3,272,000

3,940,000

$ 3,985,000

2005 Employee Stock Option and Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock reserved for issuance

4,800,000

Outstanding stock options

142,220

2015 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock reserved for issuance

3,575,000

6,000,000

Common stock reserved

11,500,000

Shares available for future grant

1,538,544

Employee Share Purchase Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Common stock reserved for issuance

4,000,000

3,251,172

Total share-based compensation

$ 519,000

484,000

481,000

Maximum percentage of gross payroll deduction

15.00%

Purchase price as a percentage of fair market value

90.00%

Maximum shares purchase in a single transaction

1,500

Maximum amount purchased in a calendar year

$ 25,000,000

Shares issued

748,828

Employee Stock Options

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Outstanding stock options

2,648,864

Total share-based compensation

$ 2,536,000

$ 3,826,000

$ 3,936,000

Total unrecognized compensation costs

$ 1,473,000

Stock option recognized over weighted average period (in years)

8 months 12 days

Employee Stock Options | 2005 Employee Stock Option and Incentive Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expiration period (in years)

10 years

Share-based compensation award plan , expiration date

May 25, 2015

Employee Stock Options | 2015 Plan

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Expiration period (in years)

10 years

Number of shares granted

0

0

326,130

Restricted Stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, number

2,263,569

Restricted Stock

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, number

2,263,569

2,312,780

1,715,958

1,820,910

Total share-based compensation

$ 16,371,000

$ 14,706,000

$ 10,875,000

Stock option recognized over weighted average period (in years)

1 year 9 months 18 days

Total unrecognized compensation costs

$ 23,277,000

Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures

1,222,863

1,529,831

885,845

Restricted Stock | Minimum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

1 year

Restricted Stock | Maximum

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Vesting period

3 years

Performance Stock Awards | Awards Granted On December 2016

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation

$ 184,000

Number of shares granted

123,082

Vesting period

4 years

Performance Stock Awards | 2015 Plan | Awards Granted On December 2016

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding, number

0

Performance Stock Units

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock option recognized over weighted average period (in years)

2 years 3 months 18 days

Total unrecognized compensation costs

$ 9,896,000

Performance Stock Units | Units Granted On October 2018

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation

458,000

$ 123,000

$ 534,000

Weighted-average grant date fair value

$ 17.84

Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures

248,140

Percentage of shares issued, minimum

50.00%

Percentage of shares issued, maximum

200.00%

Percentage of performance stock units tied to 3-year total shareholder return

34.00%

Percentage of performance stock units tied to fiscal year 2021 revenue

33.00%

Percentage performance stock units tied to fiscal year 2021 adjusted earnings per share goals

33.00%

Performance Stock Units | Units Granted On December 2019 and January 2020

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation

1,455,000

$ 309,000

Weighted-average grant date fair value

$ 16.02

Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures

279,587

Percentage of shares issued, minimum

42.50%

Percentage of shares issued, maximum

172.50%

Percentage of performance stock units tied to fiscal year 2021 revenue goal

80.00%

Percentage of performance stock units tied to fiscal year 2022 revenue goal

20.00%

Vesting period for the 3-year total shareholder return

3 years

Performance Stock Units | Units Granted On October 2020

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total share-based compensation

$ 1,187,000

Weighted-average grant date fair value

$ 16.25

Share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures

408,861

Percentage of shares issued, minimum

8.50%

Percentage of shares issued, maximum

199.50%

Percentage of performance stock units tied to fiscal year 2022 revenue goal

80.00%

Vesting period for the 3-year total shareholder return

3 years

Percentage of performance stock units tied to fiscal year 2023 revenue goal

20.00%

Share Based Awards - Summary of

Share Based Awards - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Shares, Outstanding, Beginning	3,001,350	3,166,525	3,670,170
Number of Shares, Granted			326,130
Number of Shares, Exercised	(116,916)	(55,325)	(375,645)
Number of Shares, Forfeited/Canceled	(47,350)	(75,450)	(451,730)
Number of Shares, Expired	(46,000)	(34,400)	(2,400)
Number of Shares, Outstanding, Ending	2,791,084	3,001,350	3,166,525	3,670,170
Vested and expected to vest, March 31, 2021	2,715,933
Exercisable, March 31, 2021	2,331,745
Weighted- Average Exercise Price per Share
Weighted-Average Exercise Price per Share, Outstanding, Beginning	$ 14.83	$ 15.36	$ 15.51
Weighted-Average Exercise Price per Share, Granted			16.40
Weighted-Average Exercise Price per Share, Exercised	16.21	15.87	15.49
Weighted-Average Exercise Price per Share, Forfeited/Cancelled	18.58	23.38	18
Weighted-Average Exercise Price per Share, Expired	29.17	43.04	28.15
Weighted-Average Exercise Price per Share, Outstanding, Ending	14.47	$ 14.83	$ 15.36	$ 15.51
Vested and expected to vest, March 31, 2021 (in dollars per share)	14.45
Exercisable, March 31, 2021 (in dollars per share)	$ 14.33
Weighted- Average Remaining Contractual Life (years)
Outstanding	3 years 8 months 12 days	4 years 8 months 12 days	5 years 6 months	6 years 2 months 12 days
Granted			6 years 9 months 18 days
Exercised	3 years 3 months 18 days	4 years 3 months 18 days	4 years 8 months 12 days
Forfeited/Canceled	3 years 8 months 12 days	1 year 6 months	4 years 10 months 24 days
Vested and expected to vest, March 31, 2021	3 years 8 months 12 days
Exercisable, March 31, 2021	3 years 7 months 6 days
Aggregate Intrinsic Value
Outstanding	$ 10,303		$ 7,040	$ 766
Exercised	303	$ 138	$ 1,589
Vested and expected to vest, March 31, 2021	10,075
Exercisable, March 31, 2021	$ 8,910

Share Based Awards - Summary _2

Share Based Awards - Summary of Stock Options By Grant Date (Details) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise Price Granted (in USD per share)			$ 16.40
2015 Plan | Employee Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted	0	0	326,130
2015 Plan | Employee Stock Options | May 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted			241,130
Exercise Price Granted (in USD per share)			$ 16.83
Vesting period			4 years
Expiration			Jun. 1, 2026
2015 Plan | Employee Stock Options | August 3, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted			60,000
Exercise Price Granted (in USD per share)			$ 21.27
Vesting period			4 years
Expiration			Aug. 3, 2026
2015 Plan | Employee Stock Options | November 2, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares granted			25,000
Exercise Price Granted (in USD per share)			$ 15.09
Vesting period			4 years
Expiration			Nov. 2, 2026

Share Based Awards - Schedule o

Share Based Awards - Schedule of Assumptions Used in Black-Scholes Model to Estimate Fair Value of Stock Awards (Details)	12 Months Ended
	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, minimum	34.60%
Expected volatility, maximum	36.80%
Expected dividends	0.00%
Risk-free rate, minimum	2.80%
Risk-free rate, maximum	3.10%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 1 month 6 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 3 months 18 days

Share Based Awards - Summary _3

Share Based Awards - Summary of Non-vested Stock Option (Details) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Non-Vested Number of Shares, Beginning Balance	1,091,672	1,845,855	2,657,005
Non-Vested Number of Shares Granted			326,130
Non-Vested Number of Shares Vested	(605,433)	(745,033)	(778,900)
Non-Vested Number of Shares Forfeited	(26,900)	(9,150)	(358,380)
Non-Vested Number of Shares, Ending Balance	459,339	1,091,672	1,845,855
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-Average Grant-Date Fair Value per Share, Nonvested, Beginning	$ 5.67	$ 5.52	$ 5.18
Weighted-Average Grant-Date Fair Value per Share, Granted			7.18
Weighted-Average Grant-Date Fair Value per Share, Vested	5.40	5.29	5.12
Weighted-Average Grant-Date Fair Value per Share, Forfeited	6.80	6.42	5.36
Weighted-Average Grant-Date Fair Value per Share, Nonvested, Ending	$ 5.96	$ 5.67	$ 5.52

Share Based Awards - Summary _4

Share Based Awards - Summary of Restricted Stock Awards Activity (Details) - Restricted Stock - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding Beginning Balance	2,312,780	1,715,958	1,820,910
Granted	1,222,863	1,529,831	885,845
Vested	(1,053,792)	(764,290)	(642,695)
Canceled	(218,282)	(168,719)	(348,102)
Number of Shares Outstanding Ending Balance	2,263,569	2,312,780	1,715,958
Weighted Average Grant-Date Fair Value per Share, Beginning of Period	$ 16.74	$ 16.29	$ 14.52
Weighted Average Grant-Date Fair Value per Share, Granted	12.04	16.93	18.14
Weighted Average Grant-Date Fair Value per Share, Vested	16.22	16.05	14.63
Weighted Average Grant-Date Fair Value per Share, Canceled	15.30	17.06	14.79
Weighted Average Grant-Date Fair Value per Share, End of Period	$ 14.58	$ 16.74	$ 16.29

Commitments, Guarantees and C_2

Commitments, Guarantees and Contingencies - Additional Information (Details)	12 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Applicable program documentation period	365 days

Restructuring Plan - Additional

Restructuring Plan - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	May 31, 2020	Jun. 30, 2019	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost And Reserve [Line Items]
Restructuring costs			$ 2,562	$ 2,505	$ 640
Restructuring and related cost, expected cost					$ 1,762
Research and Development Costs
Restructuring Cost And Reserve [Line Items]
Restructuring plan, percentage of number of positions eliminated		4.00%
COVID-19 Pandemic
Restructuring Cost And Reserve [Line Items]
Restructuring plan, percentage of number of positions eliminated	3.00%

Schedule II Valuation and Qua_2

Schedule II Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Sales Return Reserve
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	$ 4,191	$ 4,759	$ 5,520
Additions	6,595	7,094	4,969
Deductions	(7,193)	(7,662)	(5,730)
Balance at End of Year	3,593	4,191	4,759
Allowance for Doubtful Accounts
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	3,549	6,054	3,876
Additions	2,834	3,367	5,644
Deductions	(2,178)	(5,872)	(3,466)
Balance at End of Year	4,205	3,549	6,054
Valuation Allowance for Deferred Taxes
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year	5,452	3,563	2,893
Additions	877	327	708
Acquisition Related Additions	0	1,590	0
Deductions	(314)	(28)	(38)
Balance at End of Year	$ 6,015	$ 5,452	$ 3,563